UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________

FORM 10-Q

_______________________________

(Mark One)


x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, ~~2020~~2021


¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For transition period from ___________ to ___________.

Commission File Number: 001-37841

Kadmon Holdings, Inc.

(Exact name of registrant as specified in its charter)

_______________________________


Delaware (State or other jurisdiction of ‎incorporation or organization)		27-3576929 (I.R.S. Employer ‎Identification No.)

450 East 29th Street, New York, NY (Address of principal executive offices)		10016 (Zip Code)

(833) 900-5366

(Registrant’s telephone number, including area code)

_______________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.001 per share	KDMN	Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:


Large accelerated Filer ¨		Accelerated Filer x¨		Non-accelerated Filer ¨x		Smaller reporting company x		Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

~~Securities registered pursuant to Section 12(b) of the Act:~~

~~Title of each class~~	~~Trading Symbol(s)~~	~~Name of each exchange on which registered~~
~~Common stock, par value $0.001 per share~~	~~KDMN~~	~~Nasdaq Global Select Market~~

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of shares of the registrant’s common stock outstanding as of November ~~2, 2020~~1, 2021 was ~~171,512,945.~~178,521,071.

Table of Contents

Kadmon Holdings, Inc.

Quarterly Report Form 10-Q

Table of Contents


		Page
PART I – Financial Information
Item 1	Consolidated Financial Statements:	54
	Consolidated Balance Sheets as of September 30, ~~2020~~2021 (unaudited) and December 31, ~~2019~~2020	54
	Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, ~~2020~~2021 and ~~2019~~2020 (unaudited)	65
	Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, ~~2020~~2021 and ~~2019~~2020 (unaudited)	76
	Consolidated Statements of Cash Flowsfor the nine months ended September 30, ~~2020~~2021 and ~~2019~~2020 (unaudited)	98
	Notes to Consolidated Financial Statements (unaudited)	109
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2427
Item 3	Quantitative and Qualitative Disclosures About Market Risk	2935
Item 4	Controls and Procedures	2935

PART II – Other Information
Item 1	Legal Proceedings	3036
Item 1A	Risk Factors	3036
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	3238
Item 3	Defaults Upon Senior Securities	3238
Item 4	Mine Safety Disclosures	3238
Item 5	Other Information	3238
Item 6	Exhibits	3238

Signatures		3440

‎

Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding future expenditures, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “would,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors include, but are not limited to, the following:

~~whether~~ our ~~New Drug Application~~ability to commercialize REZUROCK™ (belumosudil) and execute on our marketing plans for ~~belumosudil will~~any other drugs or indications that may be ~~accepted by~~approved in the ~~U.S. Food~~future;

risks that REZUROCK revenue, expenses and ~~Drug Administration;~~costs may not be as expected;

risks relating to REZUROCK’s market acceptance, competition, reimbursement and regulatory actions;

our ability to obtain and maintain reimbursement for REZUROCK and any approved product and the extent to which patient assistance programs and copay programs are utilized;

our ability to manage our reliance on sole-source third parties such as our third party drug substance and drug product contract manufacturers;

the ~~initiation, timing, progress~~inherent uncertainty in estimates of patient populations and ~~results of our preclinical studies~~incidence and ~~clinical trials, and our research and development programs;~~prevalence estimates;

our ability to advance product candidates into, and successfully complete, clinical trials;

the impact of the COVID-19 pandemic on our business, workforce, patients, collaborators and suppliers, including delays in anticipated timelines and milestones of our clinical trials, ~~and~~ on various government agencies who we interact with and/or are governed ~~by;~~

~~our reliance on~~by and commercial and clinical drug supply chain continuity and the ~~success~~commercial launch of ~~our product candidates;~~REZUROCK;

the timing or likelihood of regulatory filings and approvals, especially in light of the COVID-19 pandemic;

the benefits of U.S. Food and Drug Administration (“FDA”) designations such as ~~Breakthrough Therapy, and review of our New~~the Orphan Drug ~~Application under the FDA's Oncology Center of Excellence pilot program, Real-Time Oncology Review;~~

~~the commercialization, pricing and reimbursement of our product candidates, if approved, and our ability to expand our sales and marketing capabilities;~~Designation;

the implementation of our business model, strategic plans for our business, product candidates and technology;

the scope of protection we are able to establish and maintain for intellectual property rights covering our product and product candidates and technology;

~~our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties;~~

cost associated with defending or enforcing, if any, intellectual property infringement, misappropriation or other intellectual property violation, product liability and other claims;

regulatory and governmental policy developments in the United States, Europe and other jurisdictions;

our ability to maintain and establish strategic agreements and collaborations and ~~the~~their potential ~~benefits of those arrangements;~~

~~the rate and degree of market acceptance, if any, of our product candidates, if approved;~~benefits;

developments relating to our competitors and our industry, including competing therapies;

our ability to effectively manage our anticipated growth;

our ability to attract and retain qualified employees and key personnel;

~~our ability to achieve cost savings and benefits from our efforts to streamline our operations and to not harm our business with such efforts;~~

~~our expectations regarding the period during which we qualify as an emerging growth company under the Jumpstart Our Business Startups Act;~~

statements and estimates regarding future revenue, hiring plans, operating expenses, capital expenditures, capital requirements, needs for additional financing and share performance;

litigation, including costs associated with prosecuting or defending pending or threatened claims and any adverse outcomes or settlements not covered by insurance;

our expected use of cash, ~~and~~ cash equivalents and marketable debt securities and other sources of liquidity;

our ability to manage our liquidity needs, including our ability to raise additional capital, to fund our operations or repay our debt obligations;

the future trading price of the shares of our common ~~stock and the impact of securities analysts’ reports on these prices;~~

~~Table of Contents~~

~~the future trading price of our equity investments and our potential inability to sell those securities;~~stock;

our ability to apply unused federal and state net operating loss carryforwards against future taxable income; ~~and~~and/or

other risks and uncertainties, including those listed under the caption “Risk Factors.”

In addition to the above factors, the risks and uncertainties related to the Merger (described elsewhere in this Quarterly Report on Form 10-Q) include, but are not limited to: risks related to the Company’s ability to complete the Merger on the proposed terms or on the proposed timeline, including the receipt of required regulatory approvals; the possibility that competing offers will be made; and other risks associated with executing business combination transactions, such as disruption from the proposed acquisition making it more difficult to conduct business as usual or to maintain relationships with customers, employees, manufacturers, suppliers or patient groups. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions, and we may not actually achieve the plans, intentions or expectations included in our forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.

Except as required by law, we disclaim any duty to update any forward looking statements, whether as a result of new information, future events or otherwise.

Table of Contents

PART I. FINANCIAL INFORMATION

Kadmon Holdings, Inc.

Consolidated Balance Sheets

(in thousands, except share ~~and per share~~ amounts)



	September 30,		December 31,		September 30,		December 31,
	2020		2019		2021		2020
	(unaudited)				(unaudited)
Assets
Current assets:
Cash and cash equivalents	$	105,949	$	139,597	$	68,826	$	74,423
Marketable debt securities, available-for-sale		44,514		—		182,821		49,435
Accounts receivable, net		373		954		17,975		695
Inventories, net		28		640		22		102
Prepaid expenses and other current assets		2,240		1,416		2,918		2,082
Investment, equity securities		9,238		41,997		9,196		10,564
Total current assets		162,342		184,604		281,758		137,301
Fixed assets, net		1,620		2,444		885		1,287
Right of use lease asset		17,013		19,651		13,554		16,112
Goodwill		3,580		3,580		3,580		3,580
Restricted cash		2,117		2,116		2,117		2,117
Investment, at cost		2,300		2,300		2,300		2,300
Other noncurrent assets		17		103		71		13
Total assets	$	188,989	$	214,798	$	304,265	$	162,710

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	12,110	$	9,043	$	21,360	$	10,933
Accrued expenses		10,212		14,248		15,238		11,534
Term debt - current		679		—
PPP loan - current						—		1,699
Lease liability - current		4,143		3,966		4,560		4,223
Warrant liabilities		1,016		1,485		3,408		1,082
Total current liabilities		28,160		28,742		44,566		29,471
Lease liability - noncurrent		16,631		19,759		12,223		15,579
Deferred tax liability		461		461		278		278
Term debt - noncurrent		2,378		—
Other long term liabilities		—		101
PPP loan - noncurrent						—		1,359
Convertible notes, net						233,186		—
Total liabilities		47,630		49,063		290,253		46,687
Commitments and contingencies (Note 12)
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2020 and December 31, 2019; 28,708 shares issued and outstanding at September 30, 2020 and December 31, 2019.		44,011		42,433
Common stock, $0.001 par value; 400,000,000 shares authorized at September 30, 2020 and December 31, 2019; 171,220,592 and 159,759,996 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		171		160
Convertible preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; 28,708 shares issued and outstanding at September 30, 2021 and December 31, 2020.						46,212		44,555
Common stock, $0.001 par value; 400,000,000 shares authorized at September 30, 2021 and December 31, 2020; 176,489,990 and 171,530,045 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively						176		171
Additional paid-in capital		512,904		456,211		505,250		515,429
Accumulated deficit		(415,702)		(333,069)		(538,107)		(444,104)
Noncontrolling interest						580		—
Accumulated other comprehensive loss		(25)		—		(99)		(28)
Total stockholders’ equity		141,359		165,735		14,012		116,023
Total liabilities and stockholders’ equity	$	188,989	$	214,798	$	304,265	$	162,710

See accompanying notes to consolidated financial statements (unaudited)

Table of Contents

Kadmon Holdings, Inc.

Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(in thousands, except share and per share amounts)



	Three Months Ended				Nine Months Ended				Three Months Ended				Nine Months Ended
	September 30,				September 30,				September 30,				September 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Revenues:
Net sales	$	339	$	50	$	1,227	$	164	$	12,223	$	339	$	12,607	$	1,227
Other revenue		151		176		6,446		529		2,483		151		2,859		6,446
Total revenue		490		226		7,673		693		14,706		490		15,466		7,673
Cost of sales		214		73		704		149		643		214		750		704
Write-down of inventory		148		—		1,054		932		—		148		—		1,054
Gross profit		128		153		5,915		(388)		14,063		128		14,716		5,915
Operating expenses:
Research and development		17,268		13,227		46,658		43,326		18,850		17,268		52,649		46,658
Selling, general and administrative		10,865		10,174		30,299		27,101		21,599		10,865		47,852		30,299
Total operating expenses		28,133		23,401		76,957		70,427		40,449		28,133		100,501		76,957
Loss from operations		(28,005)		(23,248)		(71,042)		(70,815)		(26,386)		(28,005)		(85,785)		(71,042)
Other income (expense) :
Other (expense) income:
Interest income		208		418		802		1,622		1,246		208		2,966		802
Interest expense		(8)		(931)		(13)		(2,799)		(2,492)		(8)		(6,218)		(13)
Realized gain on equity securities										—		4,274		—		19,784
Unrealized loss on equity securities										(1,619)		(3,254)		(1,368)		(32,759)
PPP Loan forgiveness										—		—		3,091		—
Gain on extinguishment of obligations										—		1,626		458		1,754
Change in fair value of warrant liabilities		602		(126)		469		(70)		(2,674)		602		(2,326)		469
Realized gain on equity securities		4,274		—		19,784		—
Unrealized (loss) gain on equity securities		(3,254)		(38,634)		(32,759)		22,304
Gain on extinguishment of obligation		1,626		—		1,754		—
Other (expense) income		(49)		126		(50)		115
Total other income (expense)		3,399		(39,147)		(10,013)		21,172
Other expense										(1,118)		(49)		(2,584)		(50)
Total other (expense) income										(6,657)		3,399		(5,981)		(10,013)
Loss before income tax expense		(24,606)		(62,395)		(81,055)		(49,643)		(33,043)		(24,606)		(91,766)		(81,055)
Income tax expense		—		—		—		—		—		—		—		—
Net loss	$	(24,606)	$	(62,395)	$	(81,055)	$	(49,643)	$	(33,043)	$	(24,606)	$	(91,766)	$	(81,055)
Deemed dividend on convertible preferred stock		543		517		1,578		1,540
Less: Net income attributable to noncontrolling interest										580		—		580		—
Less: Deemed dividend on convertible preferred stock										571		543		1,657		1,578
Net loss attributable to common stockholders	$	(25,149)	$	(62,912)	$	(82,633)	$	(51,183)	$	(34,194)	$	(25,149)	$	(94,003)	$	(82,633)

Basic and diluted net loss per share of common stock	$	(0.15)	$	(0.49)	$	(0.50)	$	(0.40)	$	(0.20)	$	(0.15)	$	(0.55)	$	(0.50)
Weighted average basic and diluted shares of common stock outstanding		169,310,056		128,225,469		165,107,295		128,360,618		173,443,975		169,310,056		172,373,463		165,107,295

Other comprehensive loss:
Net unrealized loss on available-for-sale securities		25		—		25		—
Other comprehensive loss		25		—		25		—
Comprehensive loss attributable to common shareholders	$	(25,174)	$	(62,912)	$	(82,658)	$	(51,183)
Other comprehensive (income) loss:
Net unrealized (gain) loss on available-for-sale securities										(66)		25		71		25
Other comprehensive (income) loss										(66)		25		71		25
Comprehensive loss attributable to common stockholders									$	(34,128)	$	(25,174)	$	(94,074)	$	(82,658)

See accompanying notes to consolidated financial statements (unaudited)

‎

Table of Contents

Kadmon Holdings, Inc.

Consolidated Statements of Stockholders’ Equity (unaudited)

(in thousands, except share amounts)


For the Three Months Ended September 30, 2021

	Preferred stock			Common stock			Additional ‎paid-in		Accumulated Other		Noncontrolling		Accumulated
	Shares	Amount		Shares	Amount		capital		Comprehensive Loss		Interest		Deficit		Total
Balance, July 1, 2021	28,708	$	45,641	171,985,864	$	171	$	491,721	$	(165)	$	—	$	(503,913)	$	33,455
Share-based compensation expense	—		—	—		—		3,523		—		—		—		3,523
Common stock issued for option and warrant exercises	—		—	4,504,126		5		10,006		—		—		—		10,011
Beneficial conversion feature on convertible preferred stock	—		114	—		—		—		—		—		(114)		—
Accretion of dividends on convertible preferred stock	—		457	—		—		—		—		—		(457)		—
Other comprehensive income	—		—	—		—		—		66		—		—		66
Net loss	—		—	—		—		—		—		580		(33,623)		(33,043)
Balance, September 30, 2021	28,708	$	46,212	176,489,990	$	176	$	505,250	$	(99)	$	580	$	(538,107)	$	14,012


For the Three Months Ended September 30, 2020

	Preferred stock			Common stock			Additional ‎paid-in		Accumulated Other		Noncontrolling		Accumulated
	Shares	Amount		Shares	Amount		capital		Comprehensive Loss		Interest		Deficit		Total
Balance, July 1, 2020	28,708	$	43,468	171,097,067	$	171	$	510,171	$	—	$	—	$	(390,553)	$	163,257
Share-based compensation expense	—		—	—		—		2,453		—		—		—		2,453
Common stock issued for option exercises	—		—	123,525		—		280		—		—		—		280
Beneficial conversion feature on convertible preferred stock	—		109	—		—		—		—		—		(109)		—
Accretion of dividends on convertible preferred stock	—		434	—		—		—		—		—		(434)		—
Other comprehensive loss	—		—	—		—		—		(25)		—		—		(25)
Net loss	—		—	—		—		—		—		—		(24,606)		(24,606)
Balance, September 30, 2020	28,708	$	44,011	171,220,592	$	171	$	512,904	$	(25)	$	—	$	(415,702)	$	141,359

See accompanying notes to consolidated financial statements (unaudited)
‎

Table of Contents

Kadmon Holdings, Inc.

Consolidated Statements of Stockholders’ Equity (unaudited)

(in thousands, except share amounts)


For the Three Months Ended September 30, 2020
For the Nine Months Ended September 30, 2021															For the Nine Months Ended September 30, 2021

	Preferred stock			Common stock			Additional paid-in		Accumulated Other		Accumulated					Preferred stock			Common stock			Additional ‎paid-in		Accumulated Other		Noncontrolling		Accumulated
	Shares	Amount		Shares	Amount		capital		Comprehensive Loss		Deficit		Total			Shares	Amount		Shares	Amount		capital		Comprehensive Loss		Interest		Deficit		Total
Balance, July 1, 2020	28,708	$	43,468	171,097,067	$	171	$	510,171	$	—	$	(390,553)	$	163,257
Balance, January 1, 2021																28,708	$	44,555	171,530,045	$	171	$	515,429	$	(28)	$	—	$	(444,104)	$	116,023
Share-based compensation expense	—		—	—		—		2,453		—		—		2,453		—		—	—		—		11,144		—		—		—		11,144
Common stock issued for option exercises	—		—	123,525		—		280		—		—		280
Common stock issued under ESPP plan																—		—	94,420		—		313		—		—		—		313
Common stock issued for option and warrant exercises																—		—	4,865,525		5		11,364		—		—		—		11,369
Payments for capped call transactions																—		—	—		—		(33,000)		—		—		—		(33,000)
Beneficial conversion feature on convertible preferred stock	—		109	—		—		—		—		(109)		—		—		331	—		—		—		—		—		(331)		—
Accretion of dividends on convertible preferred stock	—		434	—		—		—		—		(434)		—		—		1,326	—		—		—		—		—		(1,326)		—
Other comprehensive loss	—		—	—		—		—		(25)		—		(25)		—		—	—		—		—		(71)		—		—		(71)
Net loss	—		—	—		—		—		—		(24,606)		(24,606)		—		—	—		—		—		—		580		(92,346)		(91,766)
Balance, September 30, 2020	28,708	$	44,011	171,220,592	$	171	$	512,904	$	(25)	$	(415,702)	$	141,359
Balance, September 30, 2021																28,708	$	46,212	176,489,990	$	176	$	505,250	$	(99)	$	580	$	(538,107)	$	14,012


For the Three Months Ended September 30, 2019
For the Nine Months Ended September 30, 2020															For the Nine Months Ended September 30, 2020

	Preferred stock			Common stock			Additional ‎paid-in		Accumulated Other		Accumulated					Preferred stock			Common stock			Additional ‎paid-in		Accumulated Other		Noncontrolling		Accumulated
	Shares	Amount		Shares	Amount		capital		Comprehensive Loss		Deficit		Total			Shares	Amount		Shares	Amount		capital		Comprehensive Loss		Interest		Deficit		Total
Balance, July 1, 2019	28,708	$	41,398	129,634,540	$	130	$	357,443	$	—	$	(257,914)	$	141,057
Balance, January 1, 2020																28,708	$	42,433	159,759,996	$	160	$	456,211	$	—	$	—	$	(333,069)	$	165,735
Share-based compensation expense	—		—	—		—		1,462		—		—		1,462		—		—	—		—		7,111		—		—		—		7,111
Common stock issued in public offering, net																—		—	11,060,786		11		48,430		—		—		—		48,441
Common stock issued under ESPP plan																—		—	98,840		—		216		—		—		—		216
Common stock issued for warrant exercises																—		—	2,777		—		7		—		—		—		7
Common stock issued for option exercises																—		—	298,193		—		929		—		—		—		929
Beneficial conversion feature on convertible preferred stock	—		103	—		—		—		—		(103)		—		—		316	—		—		—		—		—		(316)		—
Accretion of dividends on convertible preferred stock	—		414	—		—		—		—		(414)		—		—		1,262	—		—		—		—		—		(1,262)		—
Other comprehensive loss																—		—	—		—		—		(25)		—		—		(25)
Net loss	—		—	—		—		—		—		(62,395)		(62,395)		—		—	—		—		—		—		—		(81,055)		(81,055)
Balance, September 30, 2019	28,708	$	41,915	129,634,540	$	130	$	358,905	$	—	$	(320,826)	$	80,124
Balance, September 30, 2020																28,708	$	44,011	171,220,592	$	171	$	512,904	$	(25)	$	—	$	(415,702)	$	141,359

See accompanying notes to consolidated financial statements (unaudited)

‎

~~Table of Contents~~

~~Kadmon Holdings, Inc.~~

~~Consolidated Statements of Stockholders’ Equity (unaudited)~~

~~(in thousands, except share amounts)~~

For the Nine Months Ended September 30, 2020
Preferred stock
Common stock
Additional
‎paid-in
Accumulated Other
Accumulated
Shares
Amount
Shares
Amount
capital
Comprehensive Loss
Deficit
Total
Balance, January 1, 2020
28,708
$
42,433
159,759,996
$
160
$
456,211
$
—
$
(333,069)
$
165,735
Share-based compensation expense
—
—
—
—
7,111
—
—
7,111
Common stock issued in public offering, net
—
—
11,060,786
11
48,430
—
—
48,441
Common stock issued under ESPP plan
—
—
98,840
—
216
—
—
216
Common stock issued for warrant exercises
—
—
2,777
—
7
—
—
7
Common stock issued for option exercises
—
—
298,193
—
929
—
—
929
Beneficial conversion feature on convertible preferred stock
—
316
—
—
—
—
(316)
—
Accretion of dividends on convertible preferred stock
—
1,262
—
—
—
—
(1,262)
—
Other comprehensive loss
—
—
—
—
—
(25)
—
(25)
Net loss
—
—
—
—
—
—
(81,055)
(81,055)
Balance, September 30, 2020
28,708
$
44,011
171,220,592
$
171
$
512,904
$
(25)
$
(415,702)
$
141,359

For the Nine Months Ended September 30, 2019
Preferred stock
Common stock
Additional
‎paid-in
Accumulated Other
Accumulated
Shares
Amount
Shares
Amount
capital
Comprehensive Loss
Deficit
Total
Balance, January 1, 2019
30,000
$
42,231
113,130,817
$
113
$
315,710
$
—
$
(269,643)
$
88,411
Share-based compensation expense
—
—
—
—
5,587
—
—
5,587
Common stock issued in public offering, net
—
—
16,316,805
17
35,679
—
—
35,696
Common stock issued under ESPP plan
—
—
32,273
—
73
—
—
73
Beneficial conversion feature on convertible preferred stock
—
308
—
—
—
—
(308)
—
Accretion of dividends on convertible preferred stock
—
1,232
—
—
—
—
(1,232)
—
Common stock issued upon conversion of convertible preferred stock
(1,292)
(1,856)
154,645
—
1,856
—
—
—
Net income
—
—
—
—
—
—
(49,643)
(49,643)
Balance, September 30, 2019
28,708
$
41,915
129,634,540
$
130
$
358,905
$
—
$
(320,826)
$
80,124

~~See accompanying notes~~Click or tap here to ~~consolidated financial statements (unaudited)~~enter text.

Table of Contents

Kadmon Holdings, Inc.

Consolidated Statements of Cash Flows (unaudited)

(in thousands)


	Nine Months Ended				Nine Months Ended
	September 30,				September 30,
	2020		2019			2021	2020
Cash flows from operating activities:
Net loss	$	(81,055)	$	(49,643)	$	(91,766)	$	(81,055)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of premium and discounts on available-for-sale securities		122		—		2,591		122
Amortization of debt discount						792		—
Depreciation and amortization of fixed assets		1,263		1,356		647		1,263
Non-cash operating lease cost		2,638		2,495		2,798		2,638
Write-down of inventory		1,054		932		—		1,054
Amortization of debt discount		—		283
Share-based compensation		7,111		5,587		11,144		7,111
Change in fair value of warrant liabilities		(469)		70		2,326		(469)
Net unrealized loss (gain) on equity securities		12,975		(22,304)
Gain on extinguishment of obligation		(1,754)		—
Net unrealized loss on equity securities						1,368		12,975
Gain on settlement of obligations						(3,549)		(1,754)
Changes in operating assets and liabilities:
Accounts receivable, net		581		1,003		(17,280)		581
Inventories, net		(442)		(221)		80		(442)
Prepaid expenses and other assets		(738)		346		(894)		(738)
Accounts payable		2,919		(1,402)		10,427		2,919
Lease liability		(2,951)		(2,763)		(3,259)		(2,951)
Accrued expenses and other liabilities		(2,383)		314
Accrued expenses						4,195		(2,383)
Net cash used in operating activities		(61,129)		(63,947)		(80,380)		(61,129)

Cash flows from investing activities:
Purchases of investment debt securities		(44,661)		—		(185,152)		(44,661)
Maturities of investment debt securities						49,104		—
Purchases of fixed assets		(291)		(430)		(245)		(291)
Proceeds from sale of equity securities		19,784		—		—		19,784
Net cash used in investing activities		(25,168)		(430)		(136,293)		(25,168)

Cash flows from financing activities:
Proceeds from issuance of common stock, net		48,441		35,696		—		48,441
Proceeds from issuance of term debt		3,057		—		—		3,057
Proceeds from exercise of options		929		—
Proceeds from issuance of convertible notes, net of issuance costs						232,394		—
Payments for capped call transactions						(33,000)		—
Proceeds from exercise of options and warrants						11,369		936
Proceeds from issuance of ESPP shares		216		73		313		216
Proceeds from exercise of warrants		7		—
Net cash provided by financing activities		52,650		35,769		211,076		52,650
Net decrease in cash, cash equivalents and restricted cash		(33,647)		(28,608)		(5,597)		(33,647)
Cash, cash equivalents and restricted cash, beginning of period		141,713		96,856		76,540		141,713
Cash, cash equivalents and restricted cash, end of period	$	108,066	$	68,248	$	70,943	$	108,066

Components of cash, cash equivalents and restricted cash
Cash and cash equivalents		105,949		66,132		68,826		105,949
Restricted cash		2,117		2,116		2,117		2,117
Total cash, cash equivalents and restricted cash		108,066		68,248		70,943		108,066

Supplemental cash flow disclosures:
Cash paid for interest	$	—	$	2,514	$	4,326	$	—
Non-cash investing and financing activities:
Beneficial conversion feature on convertible preferred stock		316		308		331		316
Accretion of dividends on convertible preferred stock		1,262		1,232		1,326		1,262
PPP loan forgiveness						3,091		—
Operating lease liabilities arising from obtaining right-of-use assets						240		—
Operating cash flows paid for amounts included in the measurement of lease liabilities						3,682		3,609
Unpaid fixed asset additions		148		—		—		148
Operating cash flows paid for amounts included in the measurement of lease liabilities		3,609		3,498
Operating lease liabilities arising from obtaining right-of-use assets		—		212
Common stock issued upon conversion of convertible preferred stock		—		1,856
Cumulative effect of change in accounting principle - ASC 842 adoption		—		27,083

See accompanying notes to consolidated financial statements (unaudited)

Table of Contents

Kadmon Holdings, Inc.

Notes to Consolidated Financial Statements (unaudited)

1. Organization

~~Nature of Business~~The Company

Kadmon Holdings, Inc. (together with its subsidiaries, “Kadmon” or the “Company”) is a ~~clinical-stage~~ biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address significant unmet medical needs, with a near-term clinical focus on immune and fibrotic diseases as well as immuno-oncology. The Company leverages its multi-disciplinary research and development team members to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing its small molecule and biologics platforms.

In July 2021, the U.S. Food and Drug Administration (“FDA”) approved REZUROCK™ (belumosudil) 200 mg once daily (“QD”) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (“cGVHD”) after failure of at least two prior lines of systemic therapy. REZUROCK was made available in the United States in August 2021.

Pending Acquisition by Sanofi

On September 7, 2021, Kadmon entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanofi, a French société anonyme (“Sanofi”), and Latour Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Sanofi (“Merger Subsidiary”), providing for the merger of Merger Subsidiary with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Sanofi (the “Parent”). Capitalized terms not otherwise defined in this section “Pending Acquisition by Sanofi” have the meanings set forth in the Merger Agreement.

The Company’s board of directors (the “Board”) has unanimously approved the Merger and the Merger Agreement and recommended that the stockholders of the Company adopt the Merger Agreement. At the Effective Time of the Merger:

each share of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”) issued and outstanding as of immediately prior to the Effective Time (other than Dissenting Shares, Company Common Stock held by the Company as treasury stock or owned by Parent, Merger Subsidiary or any Subsidiary of the Company or Parent) will be cancelled and cease to exist and automatically convert into the right to receive cash in an amount equal to $9.50, without interest (the “Common Stock Merger Consideration”);

each share of 5% convertible preferred stock, par value $0.001 per share, of the Company (“Company Preferred Stock”) issued and outstanding as of immediately prior to the Effective Time (other than Dissenting Shares) will be cancelled and cease to exist and automatically convert into the right to receive cash in an amount equal to the greater of (i) the Stated Liquidation Preference Amount (as defined in the Company’s Certificate of Designation dated July 26, 2016) plus any dividends (whether or not earned or declared) accrued and unpaid thereon from the last Dividend Payment Date (as defined in the Certificate of Designation) through the closing date of the Merger and (ii) the amount that would be payable per share of Company Preferred Stock if such share of Company Preferred Stock had been converted to Company Common Stock immediately prior to the effective time of the Merger (the “Preferred Stock Merger Consideration”);

all unvested options to purchase Company Common Stock (“Company Options”) which are outstanding immediately prior to the Effective Time will fully vest and become exercisable and, to the extent not exercised prior to the Effective Time, be canceled at the Effective Time with the former holder of such canceled Company Option becoming entitled to receive an amount in cash (without interest and subject to any applicable withholding or other taxes, or other amount as required by law) equal to (1) the number of shares of Company Common Stock subject to such Company Option multiplied by (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price per share of such Company Option; provided that each Company Option with an exercise price per share equal to or greater than the Common Stock Merger Consideration will be canceled without consideration;

‎

Table of Contents

all unvested stock appreciation rights granted by the Company (“Company SARs”) which are outstanding as of immediately prior to the Effective Time will fully vest and, to the extent not exercised prior to the Effective Time, be canceled at the Effective Time, with the former holder of such canceled Company SAR becoming entitled to receive an amount in cash (without interest and subject to any applicable withholding or other taxes, or other amount as required by law) equal to (A) the excess, if any, of the Common Stock Merger Consideration over the exercise price per share of such Company SAR multiplied by (B) the number of shares of Company Common Stock underlying such Company SAR; provided that each Company SAR with an exercise price per share equal to or greater than the Common Stock Merger Consideration will be canceled without consideration; and

all unvested equity appreciation rights granted by the Company (“Company EARs”) which are outstanding as of immediately prior to the Effective Time will fully vest and be canceled at the Effective Time, with the former holder of such canceled Company EAR becoming entitled to receive an amount in cash (without interest and subject to any applicable withholding or other taxes, or other amount as required by law) equal to (A) the excess of the Common Stock Merger Consideration over the base price per share of such Company EAR multiplied by (B) the number of shares of Common Stock underlying such Company EAR; provided that each Company EAR with a base price per share equal to or greater than the Common Stock Merger Consideration will be canceled without consideration.

Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal impediments and approval by the holders of a majority of the voting power of the outstanding shares of Company Common Stock and Company Preferred Stock, voting on an as converted to Company Common Stock basis, entitled to vote on such matter.

The Company has made representations and warranties in the Merger Agreement and has agreed to covenants regarding the operation of the business of the Company and the Company Subsidiaries prior to the Effective Time. The Company is also subject to customary restrictions on its ability to solicit alternative acquisition proposals from third parties and to provide non-public information to, and participate in discussions and engage in negotiations with, third parties regarding alternative acquisition proposals. The Merger Agreement also contains customary covenants requiring the Board, subject to certain exceptions, to recommend that the Company’s stockholders approve the Merger. Prior to the approval of the Merger by the Company’s stockholders, the Board may withhold, withdraw, qualify, or modify its recommendation that the Company’s stockholders approve the Merger because of a Company Intervening Event or may adopt, approve or recommend any Superior Proposal, subject to complying with notice and other specified conditions.

The Merger Agreement contains certain termination rights for both the Company and Parent, including that, subject to certain limitations, (i) the Company or Parent may terminate the Merger Agreement if the Merger is not consummated by March 7, 2022, (ii) the Company and Parent may mutually agree to terminate the Merger Agreement, (iii) the Company may terminate the Merger Agreement to accept a Superior Proposal and (iv) Parent may terminate the Merger Agreement because the Board changes its recommendation to the Company stockholders with respect to approval of the Merger.

The Company will be required to pay a termination fee of $60.1 million in the event that the Company terminates the Merger Agreement to accept a Superior Proposal or if Parent terminates the Merger Agreement because the Board changes its recommendation to the Company’s stockholders to approve the Merger. In addition, the Company will be required to pay the termination fee under specified circumstances if, within 12 months after the termination of the Merger Agreement, the Company enters into or consummates a Competing Acquisition Transaction.

The foregoing description of the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement, which is attached as an exhibit to our Current Report on Form 8-K filed with the SEC on September 8, 2021 and incorporated herein by reference.

In connection with the approval of the Merger Agreement, the Board approved certain amendments to the employment agreements between the Company and each of Harlan W. Waksal, M.D., the Company’s President and Chief Executive Officer, Steven Meehan, the Company’s Executive Vice President and Chief Financial Officer, and Gregory S. Moss, the Company’s Executive Vice President, General Counsel and Corporate Secretary, Chief Compliance Officer (the “Employment Agreement Amendments”). The Employment Agreement Amendments provide for the payment of retention bonuses in the amount of $3.5 million to Dr. Waksal and $1.0 million to each of Mr. Meehan and Mr. Moss (the “Retention Bonuses”). The Retention Bonuses shall be paid as follows: (1) 25% of the Retention Bonus shall be paid on the date the Merger Agreement is fully executed and (2) the remaining 75% of the Retention Bonus will be earned at the Closing Date, subject to the executive’s continuous and active employment with the Company through such date, with certain exceptions.

The Company incurred transaction-related costs of approximately $6.0 million for the three and nine months ended September 30, 2021, inclusive of $1.4 million related to the Employment Agreement Amendment, which are recorded as selling, general and administrative expense in the consolidated financial statements.

Table of Contents

COVID-19 Update

The ongoing COVID-19 pandemic has severely impacted global economic activity and caused significant volatility in financial markets. While the Company’s financial condition, results of operations, cybersecurity and liquidity have not been materially impacted by the direct effects of the pandemic, the COVID-19 pandemic continues to evolve. The Company is continuing to monitor developments with respect to the COVID-19 pandemic and to make adjustments as needed to assist in protecting the safety of the Company’s employees and communities while continuing business activities. To date, implementation of these measures has not required material expenditures or significantly impacted these unaudited financial statements. The Company is continuing to monitor the potential impacts of COVID-19 on its operations and those of its partners, suppliers, customers, and regulators, including commercial and clinical drug supply chain continuity and commercial launch of REZUROCK.

Notwithstanding the foregoing, the Company cannot precisely predict the impact that the COVID-19 pandemic will have in the future due to numerous uncertainties, including the severity of the disease and its variants, the duration of the pandemic, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in the Company’s supply chain. The Company will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to its business, consolidated results of operations, and financial condition.

Liquidity

The Company maintained cash, cash equivalents and marketable debt securities of ~~$150.5~~$251.6 million at September 30, ~~2020.~~2021. The Company had an accumulated deficit of ~~$415.7~~$538.1 million and working capital of ~~$134.2~~$237.2 million at September 30, ~~2020. The Company entered into a Sales Agreement with Cantor Fitzgerald & Co. (“Cantor”) in August 2017 under which~~2021. On February 16, 2021, the Company ~~could sell up to $50.0~~issued $240.0 million ~~in shares~~aggregate principal amount of ~~its common stock in one or more placements at prevailing market prices for its common stock~~3.625% convertible senior notes due 2027 (the ~~“ATM Program”~~"Notes")~~. Any such sales would be effected~~, pursuant to an Indenture dated February 16, 2021, between the ~~Company’s registration statement on Form S-3 (File No. 333-233766), which was declared effective by~~Company and U.S. Bank National Association, as trustee, in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities ~~Exchange Commission (“SEC”) on September 24, 2019. In May 2020,~~Act. On February 10, 2021, concurrently with the ~~Company sold 11,060,786 shares~~pricing of ~~common stock at a weighted average price of $4.52 per share through~~ the ATM Program and received total net proceeds of $48.5 million (net of $1.5 million of commissions payable by the Company to Cantor). Under this registration statement, the Company registered to sell, in one or more transactions, up to $200.0 million of common stock, preferred stock, debt securities, warrants, purchase contracts and units. The Company had sold securities totaling an aggregate of $151.5 million pursuant to this registration statement as of September 30, 2020. In May 2020,Notes, the Company entered into ~~a single transaction pursuant to which it sold approximately 1.1 million ordinary shares of MeiraGTx Holdings plc (“MeiraGTx”~~privately negotiated capped call transactions (the “Capped Call Transactions”) for gross proceeds of $15.5 million. In July 2020, the Company entered into an additional single transaction pursuant to which it sold approximately 0.3 million ordinary shares of MeiraGTx for gross proceeds of $4.2 million.with certain financial institutions. The Company ~~expects that~~used approximately $33.0 million of the net proceeds from the Notes offering to pay for the cost of the Capped Call Transactions (Note 5). The net proceeds from the offering were $199.4 million after deducting issuance costs and the cost of Capped Call Transactions.

Based on the Company’s expectations for revenue, operating expenses, and its cash, cash equivalents and marketable debt securities available on hand at September 30, 2021, the Company believes it will ~~enable it~~continue to be able to advance its ~~planned~~ commercial launch efforts for ~~belumosudil, if approved,~~REZUROCK^™ (belumosudil), advance certain of its other pipeline product candidates, including KD033, and ~~KD045, and~~ provide for other working capital ~~purposes.~~purposes. Although cash, cash equivalents and marketable debt securities available at September 30, 2021 is expected to execute the Company’s current business plans, it may not be sufficient to enable the Company to meet its long-term expected plans. The Company has sustained operating losses for the majority of its corporate history and the Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.

The Company’s future liquidity needs and ability to address those needs will be largely determined by the success of operations in regard to the successful commercialization of REZUROCK and the progression of its product candidates in the future, scope and magnitude of its commercial expenses and key development and regulatory events in the future. Management’s plans may include continuing to finance operations through the issuance of debt and sale of additional equity securities, monetization of assets, ~~including the Company’s ownership of MeiraGTx ordinary shares,~~ and expanding the Company’s commercial portfolio through the development of its current pipeline or through strategic collaborations. The Company has no commitments for any additional financing and may not be successful in its efforts to raise additional funds or achieve profitable operations. Any transactions that occur may contain covenants that restrict the ability of management to operate the business or may have rights, preferences or privileges senior to the Company’s common stock and may dilute current stockholders of the Company.

The Company ~~also~~ filed a shelf registration statement on Form S-3 (File No. 333-238969) on June 5, 2020, which was declared effective by the ~~SEC~~U.S. Securities and Exchange Commission (“SEC”) on June 16, 2020. Under this registration statement, the Company may sell, in one or more transactions, up to $300.0 million of common stock, preferred stock, debt securities, warrants, purchase contracts and ~~units, an amount which includes $50.0 million of shares of its common stock that may be issued in the ATM Program under the Sales Agreement with Cantor.~~units. The Company had not sold any securities pursuant to this registration statement as of September 30, ~~2020.~~2021.

The ~~accompanying financial statements have been prepared~~Company entered into a Sales Agreement with Cantor Fitzgerald & Co. in ~~accordance with accounting principles generally accepted in the United States of America (“GAAP”),~~August 2017 under which ~~contemplate continuation of~~ the Company ~~as a going concern.~~could sell up to $50.0 million in shares of its common stock in one or more placements at prevailing market prices for its common stock (the “ATM Program”). The Company has not ~~established a source~~sold any securities pursuant to this ATM Program as of revenues sufficient to cover its operating costs, and as such, has been dependent on funding operations through the issuance of debt and sale of equity securities. Since inception, the Company has experienced significant losses and incurred negative cash flows from operations. The Company expects to incur further losses over the next several years as it develops its business. The Company has spent, and expects to continue to spend, a substantial amount of funds in connection with implementing its business strategy, including its planned product development efforts, preparation for its planned clinical trials, performance of clinical trials and its research and discovery efforts.September 30, 2021.

1011

Table of Contents

~~The Company’s cash, cash equivalents and marketable debt securities will not be sufficient to~~ enable the Company to meet its long-term expected plans, including commercialization of clinical pipeline products, if approved, or initiation or completion of future registration studies. Additionally, the COVID-19 pandemic has had a negative near-term impact on capital markets and may impact the Company’s ability to access capital.

The Company has no current commitments for additional financing and may not be successful in its efforts to raise additional funds or achieve profitable operations, and there can be no assurance that additional financing will be available to the Company on commercially acceptable terms or at all. Any amounts raised will be used for further development of the Company’s product candidates, for marketing and promotion, to secure additional property and equipment and for other working capital purposes.

If the Company is unable to obtain additional capital (which is not assured at this time), its long-term business plan may not be accomplished and the Company may be forced to curtail or cease operations. These factors individually and collectively raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments or classifications that may result from the possible inability of the Company to continue as a going concern.

2. Summary of Significant Accounting Policies

Basis of Presentation

The Company operates in 1 segment considering the nature of the Company’s products and services, class of customers, methods used to distribute its products and the regulatory environment in which the Company operates. The accompanying consolidated financial statements, which include the accounts of Kadmon Holdings, Inc. and its domestic and international subsidiaries ~~all of which are wholly owned by Kadmon Holdings, Inc.,~~ have been prepared in accordance with ~~GAAP~~accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company’s opinion, the financial statements include all adjustments (consisting of normal recurring adjustments) and disclosures considered necessary in order to make the financial statements not misleading. Operating results for the three and nine months ended September 30, ~~2020~~2021 are not necessarily indicative of the final results that may be expected for the year ending December 31, ~~2020.~~2021.

These unaudited financial statements should be read in conjunction with the audited financial statements included in Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020, filed with the SEC on March 4, 2021.

Use of Estimates

The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates. The most significant estimates are related to share-based compensation (Note 10) and the accrual of research and development and clinical trial expenses (Note 11).

Critical Accounting Policies

The Company’s significant accounting policies are disclosed in the audited financial statements included in Item 8 of the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020, filed with the SEC on March 4, 2021. Since the date of such financial statements, there have been no changes or updates to the Company’s significant accounting policies, other than those described below.

~~Debt~~

On April 15, 2020, the Company received the proceeds from a loan in the amount of approximately $3.1 million (the “Loan”) from PNC Bank, National Association, as lender, pursuant to the Paycheck Protection Program (“PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The Loan matures on April 15, 2022 and bears interest at a rate of 1% per annum. On August 20, 2020, the loan was amended so that, commencing August 15, 2021, the Company is required to pay the lender equal monthly payments of principal and interest as required to fully amortize by April 15, 2022 the principal amount outstanding on the Loan as of October 15, 2020. The Loan is evidenced by a promissory note dated April 15, 2020 (the “Note”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

~~Table of Contents~~

The application for these funds required the Company to certify in good faith that the then current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further required the Company to take into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The Company made this good faith assertion based upon various factors, including the degree of uncertainty introduced to the capital markets as a result of the COVID-19 pandemic and the Company’s dependency on its ability to raise capital to fund ongoing operations.

All or a portion of the Loan may be forgiven by the U.S. Small Business Administration (“SBA”) upon application by the Company upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of eligible and documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the eight-week period beginning on the date of loan approval. If, despite the Company’s good-faith belief that given the circumstances the Company satisfied all eligibility requirements for the Loan, the Company is later determined to have violated any applicable laws or regulations or it is otherwise determined that the Company was ineligible to receive the Loan, the Company may be required to repay the Loan in its entirety and/or be subject to additional penalties. In the event the Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal.

The Company used all proceeds from the Loan to retain employees, maintain payroll and make lease, rent and utility payments. Under the terms of the loan, the Company may be eligible for full or partial loan forgiveness. The Company has begun preparations to apply for forgiveness, however, no assurance is provided that the Company will obtain forgiveness for any portion of the Loan.

~~The Company has accounted for the Loan as a debt instrument~~ ~~in accordance with~~ ~~Financial Accounting Standards Board (“FASB”)~~ ~~Accounting Standards Codification (“ASC”)~~ ~~470,~~ ~~Debt. At September 30, 2020, $0.7 million of principal payments due in the third quarter of 2021 have been recorded as short-term debt and the remaining balance of $2.4~~ ~~million is recorded as long-term debt. The Company does not expect to incur any material interest expense under the Loan.~~

Cash, Cash Equivalents and Marketable Debt Securities

The Company considers all highly liquid securities with an original or remaining maturity of three months or less at the time of acquisition to be cash equivalents.

Marketable debt securities are considered to be available-for-sale and are carried at fair market value. The estimated fair value of the available-for-sale marketable debt securities is determined based on quoted market prices or rates for similar instruments. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in other (expense) income. Realized gains and losses, and declines in value judged to be other-than-temporary, if any, are also included in other (expense) income. Interest and dividends on available-for-sale securities are included in other income.

The Company determines the appropriate classification of its investments in debt securities at the time of purchase. All of the Company’s debt securities are classified as available-for-sale and are reported as short-term or long-term based on maturity dates and whether such assets are available for use in current operations and are reasonably expected to be realized in cash or ~~sold or~~ consumed during the normal cycle of business. Our available-for-sale debt securities generally have contractual maturity dates between six and eighteen months.

The Company reviews investments for other-than-temporary impairment whenever the fair value of an investment is less than the amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company experienced a credit loss and have the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance withfollowing tables summarize the Company’s ~~investment policy, the severity~~cash, cash equivalents and ~~the duration~~marketable debt securities as of ~~the impairment~~September 30, 2021 and ~~changes in value subsequent to the end of the period.~~December 31, 2020 (in thousands):



	September 30, 2021

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Cash and cash equivalents:
Cash and money market funds	$	68,826	$	—	$	—		68,826
Total cash and cash equivalents		68,826		—		—		68,826
Marketable debt securities:
Corporate debt securities		182,920		11		(110)		182,821
Total marketable debt securities		182,920		11		(110)		182,821
Total cash, cash equivalents and marketable debt securities	$	251,746	$	11	$	(110)	$	251,647

Table of Contents

~~The following table summarizes the Company’s cash, cash equivalents and marketable debt securities as of September 30, 2020 and December 31, 2019:~~

September 30, 2020
Amortized Cost
Gross Unrealized Gains
Gross Unrealized Losses
Fair Value
Cash and cash equivalents:
Cash and money market funds
$
103,126
$
—
$
—
103,126
Corporate debt securities
2,823
—
—
2,823
Total cash and cash equivalents
105,949
—
—
105,949
Marketable debt securities:
Corporate debt securities
44,540
2
(28)
44,514
Total marketable debt securities
44,540
2
(28)
44,514
Total cash, cash equivalents and marketable debt securities
$
150,489
$
2
$
(28)
$
150,463


	December 31, 2019								December 31, 2020

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Cash and cash equivalents:
Cash and money market funds	$	139,597	$	—	$	—		139,597	$	71,382	$	—	$	—		71,382
Corporate debt securities										3,041						3,041
Total cash and cash equivalents		139,597		—		—		139,597		74,423		—		—		74,423
Marketable debt securities:
Corporate debt securities		—		—		—		—		49,463		4		(32)		49,435
Total marketable debt securities		—		—		—		—		49,463		4		(32)		49,435
Total cash, cash equivalents and marketable debt securities	$	139,597	$	—	$	—	$	139,597	$	123,886	$	4	$	(32)	$	123,858

At September 30, ~~2020,~~2021, the Company had invested in 1529 available-for-sale marketable debt securities that were in an unrealized loss position for less than one year and 0 securities in an unrealized loss position for more than ~~12 months.~~one year. The aggregate fair value of debt securities in an unrealized loss position at September 30, ~~2020~~2021 was ~~$36.7~~$133.2 million. The unrealized losses of ~~less than~~ $0.1 million related to these corporate debt securities were included in accumulated other comprehensive loss as of September 30, ~~2020.~~2021. Unrealized losses on corporate debt securities have not been recognized into income because the issuers’ bonds are of high credit quality (rated A3/A- or higher), ~~management does not intend to sell and~~ it is likely that management will not be required to sell the securities prior to their anticipated recovery, and the decline in fair value is largely due to market conditions and/or changes in interest rates. The issuers continue to make timely interest payments on the bonds. The fair value is expected to recover as the bonds approach maturity and the Company does not believe any unrealized losses represent other-than-temporary impairments.

Convertible Notes Transaction

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-06, “Debt with Conversion and Other Options and Derivatives and Hedging - Contracts in Entity’s Own Equity” (“ASU 2020-06”) to address the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. This ASU includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments by eliminating the cash conversion accounting model for convertible instruments. The Company early adopted ASU 2020-06 effective January 1, 2021, and the standard did not have a significant impact on its consolidated financial statements. By adopting ASU 2020-06, the Company eliminates the separation model for convertible debt and the requirement to separately present in equity an embedded conversion feature in such debt.

In February 2021, the Company issued $240.0 million in aggregate principal of 3.625% convertible senior notes due February 15, 2027 (Note 5). The Company accounts for the convertible notes wholly as debt in accordance with FASB Accounting Standards Codification (“ASC”) 470, Debt. The Company does not separately account for the liability and equity components of convertible notes transactions that can be settled in cash by allocating the proceeds from issuance between the liability component and the embedded conversion option. The Company recognizes amortization of the debt discount related to issuance costs as interest expense using the effective interest method.

In February 2021, the Company purchased capped call options from financial institutions to minimize the impact of potential dilution of Kadmon common stock upon conversion of the convertible notes. The capped call options meet the definition of a derivative in accordance with FASB ASC 815, Derivatives and Hedging (“ASC 815”), however, qualify for derivative scope exception under ASC 815 for instruments indexed to a company’s own stock. Accordingly, the premiums for the capped call options were recorded as additional paid-in capital on the Company’s consolidated balance sheet as the options are settleable in Kadmon common stock at the election of the Company. See Note 5 for additional information.

Embedded Derivatives

The Company accounts for derivative financial instruments as either equity or liabilities in accordance with ASC 815, based on the characteristics and provisions of each instrument. Embedded derivatives are required to be bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments on the date of issuance. The Company’s convertible notes (Note 5) contain certain features that, in accordance with ASC 815, are not clearly and closely related to the host instrument and represent derivatives that are required to be re-measured at fair value each reporting period. The Company determined that the estimated fair value of the derivatives at issuance and as of September 30, 2021 were not material based on a scenario-based cash flow model that uses unobservable inputs that reflect the Company’s own assumptions. Should the Company’s assessment of the probabilities around these scenarios change, including due to changes in market conditions, there could be a change to the fair value.

Table of Contents

Revenue Recognition

The Company recognizes revenue in accordance with FASB ASC 606, Revenue from Contracts with Customers, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

Disaggregation of Revenue

The Company’s revenues have primarily been generated through product sales, collaborative research, development and commercialization license agreements, and other service agreements. The following table summarizes revenue from contracts with customers for the three and nine months ended September 30, ~~2020~~2021 and ~~2019~~2020 (in thousands):


									Three Months Ended				Nine Months Ended
	Three Months Ended				Nine Months Ended				September 30,				September 30,
	September 30,				September 30,				2021		2020		2021		2020
	2020		2019		2020		2019
Product sales	$	339	$	50	$	1,227	$	164
Product sales, net
REZUROCK									$	12,215	$	—	$	12,215	$	—
Other										8		339		392		1,227
Total product sales, net									$	12,223	$	339	$	12,607	$	1,227
License revenue		—		—		6,000		—		2,000		—		2,000		6,000
Other revenue		151		176		446		529		483		151		859		446
Total revenue	$	490	$	226	$	7,673	$	693	$	14,706	$	490	$	15,466	$	7,673

Product Sales

These contracts typically include a single promise to deliver a fixed amount of product to ~~the~~a customer with payment due within 30-60 days of ~~shipment.~~shipment, with a prompt pay discount for payments made within the terms of the applicable contract. Revenues are recognized when control of the promised goods is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those ~~goods.~~goods, which generally occurs upon delivery. The timing of revenue recognition may differ from the timing of invoicing to customers. The Company has not recognized any assets for costs to obtain or fulfill a contract with a customer as of September 30, ~~2020.~~2021.

On July 16, 2021, the FDA approved REZUROCK for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy. The Company expects REZUROCK to be its principal source of product sales in the future. For REZUROCK, the Company will classify payments to its customers for certain services provided by its customers as reductions to revenue.

The Company sells REZUROCK to patients through a limited distribution network of specialty pharmacy and specialty distributors in the United States. Net revenue from sales of REZUROCK will be recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (i) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (ii) estimated chargebacks, (iii) estimated costs of co-payment assistance programs and (iv) product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or as a current liability. Where appropriate, these estimates take into consideration items such as the Company’s current contractual and statutory requirements and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

‎

Table of Contents

Government and Managed Care Rebates. The Company contracts with government agencies and managed care organizations or, collectively, third-party payors, so that REZUROCK will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) product distribution information obtained from the Company's distribution network of specialty pharmacy and specialty distributors. During the three and nine months ended September 30, 2021, the Company recognized $0.7 million of rebates expense as a reduction to revenue related to REZUROCK and has recorded a current liability of $0.7 million in the consolidated balance sheets as of September 30, 2021.

Chargebacks. Chargebacks are discounts that occur when certain contracted customers, pharmacy benefit managers, insurance companies, government programs and group purchasing organizations purchase directly from the Company’s specialty distributors. These customers purchase the Company’s product under contracts negotiated between them and the Company’s specialty distributors. The specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor paid and the negotiated price paid by the contracted customers, which may be higher or lower than the specialty distributor’s purchase price from the Company. The Company estimates chargebacks and adjusts gross product revenues and accounts receivable based on the estimates at the time revenues are recognized. During the three and nine months ended September 30, 2021, the Company recognized $0.8 million of chargebacks expense as a reduction to revenue related to REZUROCK and has recorded a current liability of $0.2 million in the consolidated balance sheet as of September 30, 2021.

Co-payment assistance and patient assistance programs. Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and co-payment assistance utilization reports received from the Company’s hub services provider, the Company is able to estimate the co-payment assistance amounts, which are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company also offers a patient assistance program that provides free drug product, for a limited period of time, to allow a patient’s insurance coverage to be established. Based on patient assistance program utilization reports provided by the Company’s hub services provider, the Company records gross revenue of the product provided and a full reduction of the revenue amount for the free drug discount. During the three and nine months ended September 30, 2021, the Company recognized $0.1 million of co-payments assistance expense as a reduction to revenue related to REZUROCK and has recorded a current liability of $0.1 million in the consolidated balance sheet as of September 30, 2021.

Product returns. The Company provides contractual return rights to its customers, based on product dating and in instances where the product is damaged or defective. Non-acceptance of shipped drug product is reflected as a reversal of sales in the period in which the sales were originally recorded. Reserves for estimated returns are recorded as a reduction of revenue in the period that the related revenue is recognized, as well as a liability. Estimates of returns are based on third party analogs of recent drug product launches and quantitative information provided by the Company's distribution network of specialty pharmacies and specialty distributors. During the three and nine months ended September 30, 2021, the Company recognized $0.2 million of returns expense as a reduction to revenue related to REZUROCK and has recorded a liability of $0.2 million in the consolidated balance sheet as of September 30, 2021.

License Revenue

License revenue in 2021 consists of a milestone payment earned pursuant to a strategic partnership entered into with BioNova Pharmaceuticals Ltd. to develop belumosudil (KD025) in China. The transaction price of $2.0 million was allocated to the single combined performance obligation under the contract and the performance obligation was completed during the third quarter of 2021. License revenue in 2020 consists of a milestone payment earned pursuant to a joint venture and license agreement entered into with Meiji Seika Pharma Co., Ltd (“Meiji”) to develop belumosudil (KD025) in Japan (Note 9). As of December 31, 2019, the Company had 1 performance obligation related to a license agreement with Meiji that had not yet been satisfied and for which the upfront cash payment had not been received.Japan. The transaction price of $6.0 million was allocated to the single combined performance obligation under the contract and the performance obligation was completed during the first quarter of 2020. There are 0 performance obligations that have not yet been satisfied and there is no transaction price allocated to future performance obligations as of September 30, ~~2020.~~2021.

Other Revenue

The other revenue generated by the Company is primarily related to a sublease agreement with MeiraGTx ~~(Note 8)~~Holdings plc (“MeiraGTx”). The Company recognizes revenue related to sublease agreements as they are performed.

Table of Contents

Cost of Sales

Cost of product sales includes the cost of producing and distributing inventories that are related to product revenue during the respective period, including royalties owed under license agreements (Note 9). In addition, shipping and handling costs for product shipments are recorded as incurred.

Concentration and Credit Risks

Risks from Third-Party Manufacturing and Distribution Concentration

The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on a limited number of distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future inventory procurement of the Company’s product candidates.

Credit Risk

The Company’s receivables from sales of REZUROCK are primarily due from sixcustomers, accounting for approximately 96% of receivables from sales of REZUROCK and approximately 64% of total receivables, resulting in a concentration of credit risk. Sales of REZUROCK occur once an order of product has been received by the specialty pharmacy or specialty distributor customer.

Aditionally, the Company’s receivables include approximately $6.4 million due from one customer related to a collaboration agreement. This receivable accounts for approximately 36% of total receivables, resulting in a credit risk.

Related Party Transactions

The Company’s related party transactions are disclosed in the audited financial statements included in “Note 2. Summary of Significant Accounting Policies–Related Party Transactions” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Since the date of such financial statements, there have been no changes to the Company’s related party transactions.

Recent Accounting Pronouncements

In December 2019, the FASB issued ~~Accounting Standards Update (“ASU”)~~ASU No. 2019-12, “Income Taxes: Simplifying the Accounting for Income Taxes”, which removes certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. The ASU is effective for annual or interim periods beginning after December 15, 2020, with early adoption permitted. The Company does not expect the standard to have a significant impact on its consolidated financial statements.

~~In November 2018, the FASB issued ASU No. 2018-18,~~ ~~“Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606”~~, which requires transactions in collaborative arrangements to be accounted for under ASC 606 if the counterparty is a customer for a good or service (or bundle of goods and services) that is a distinct unit of account. The ASU also precludes entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The Company adopted this standard on

~~Table of Contents~~

January 1, ~~2020,~~2021, and the standard did not have a significant impact on its consolidated financial ~~statements as the Company does not have any material agreements that are within the scope of this ASU.~~

~~In August 2018, the FASB issued ASU No. 2018-15,~~ “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force)”, which requires customers in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40 to determine which implementation costs to capitalize. The Company adopted this standard on January 1, 2020, and the standard did not have a significant impact on its consolidated financial statements as the Company’s cloud computing contracts are not material.

~~In January 2017, the FASB issued ASU No. 2017-04,~~ ~~“Intangibles – Goodwill and Other”~~, which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead of performing Step 2 to determine the amount of an impairment charge, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the value by which the carrying amount exceeds the reporting unit’s fair value. For smaller reporting companies, ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this standard on April 1, 2020, and the standard did not have a significant impact on its consolidated financial statements as the Company’s goodwill is not material.statements.

In June 2016, the FASB issued ASU No. 2016-13, “Measurement of Credit Losses on Financial Instruments”, to require financial assets carried at amortized cost to be presented at the net amount expected to be collected based on historical experience, current conditions and forecasts. For smaller reporting companies, the ASU is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. Adoption of the ASU is on a modified retrospective basis. The Company does not expect this guidance to have a material impact on its financial statements.

3. Stockholders’ Equity

5% Convertible Preferred Stock

The Company had 28,708 shares of 5% convertible preferred stock outstanding at September 30, ~~2020,~~2021, which shares convert into shares of the Company’s common stock at a 20% discount to the initial public offering price per share of common stock in the Company’s initial public offering ~~(the “IPO”)~~ of $12.00 per share, or $9.60 per share. The stated liquidation preference amount on the 5% convertible preferred stock totaled ~~$34.8~~$36.5 million at September 30, ~~2020.~~2021.

Common Stock

The Company’s restated certificate of incorporation authorizes the issuance of up to 400,000,000 shares of the Company’s common stock, par value $0.001 per share.

‎

1516

Table of Contents

4. Net Loss per Share Attributable to Common Stockholders

Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. ~~Shares issued during the period are weighted for the portion of the period during which they were outstanding.~~ Because the Company has reported a net loss for each period presented, diluted net loss per share of common stock is the same as basic net loss per ~~shares~~share of common stock for the three and nine months ended September 30, ~~2020~~2021 and ~~2019.~~ 2020.

The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):


	Three Months Ended				Nine Months Ended				Three Months Ended				Nine Months Ended
	September 30,				September 30,				September 30,				September 30,
	2020		2019		2020			2019	2021		2020		2021			2020
Numerator – basic and diluted:
Net loss available to common stockholders - basic and diluted	$	(25,149)	$	(62,912)	$	(82,633)	$	(51,183)	$	(34,194)	$	(25,149)	$	(94,003)	$	(82,633)
Denominator – basic and diluted:
Weighted average shares of common stock outstanding used to compute basic and diluted net loss per share		169,310,056		128,225,469		165,107,295		128,360,618		173,443,975		169,310,056		172,373,463		165,107,295
Net loss per share, basic and diluted	$	(0.15)	$	(0.49)	$	(0.50)	$	(0.40)	$	(0.20)	$	(0.15)	$	(0.55)	$	(0.50)

The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:


	Three Months Ended		Nine Months Ended		Three and Nine Months Ended
	September 30,		September 30,		September 30,
	2020	2019	2020	2019	2021	2020
Options to purchase common stock	17,357,285	11,999,752	17,357,285	11,999,752	24,310,370	17,357,285
Warrants to purchase common stock	11,917,052	11,999,852	11,917,052	11,999,852	6,261,586	11,917,052
Convertible preferred stock	3,667,651	3,493,002	3,667,651	3,493,002	3,851,033	3,667,651
Convertible notes					34,507,560	—
Total shares of common stock equivalents	32,941,988	27,492,606	32,941,988	27,492,606	68,930,549	32,941,988

5. Debt

3.625% Convertible Senior Notes Due in 2027

In February 2021, the Company issued $240.0 million in aggregate principal of 3.625% convertible senior notes due February 15, 2027 (the "Notes") through a private placement to qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended. The debt issuance costs of $7.6 million were recorded as a debt discount and are being amortized to interest expense over the contractual term of the Notes.

The Notes, governed by an indenture between the Company and a trustee, are senior, unsecured obligations and do not include financial and operating covenants nor any restrictions on the payments of dividends, the incurrence of indebtedness or the issuance or repurchase of securities by Kadmon or any of its subsidiaries. Interest on the Notes is payable semi-annually in cash in arrears at a rate of 3.625% per annum on February 15 and August 15 of each year. The Notes will mature February 15, 2027 unless they are redeemed, repurchased or converted prior to such date. Before November 15, 2026, noteholders will have the right to convert their Notes only upon the occurrence of certain events. From and after November 15, 2026, noteholders may convert their Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date.

Upon conversion, the Notes may be settled in shares of Kadmon common stock, cash or a combination thereof, at the Company’s election. The initial conversion rate is 143.7815 shares of common stock per $1,000 in principal amount of Notes, which represents an initial conversion price of approximately $6.96 per share of common stock, or a premium of approximately 30% to the $5.35 per share closing price of the Company’s common stock on February 10, 2021, the date the Company priced the offering. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events. In addition, if certain corporate events that constitute a “Make-Whole Fundamental Change” (as defined in the applicable indenture) occur, then the conversion rate will, in certain circumstances, be increased for a specified period of time.

Table of Contents

The Company may redeem all or any portion of the Notes, at its option, on or after February 20, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, up to, but excluding, the redemption date, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least each of 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately before the date the Company provides written notice of redemption; and the trading day immediately before the notice is sent. In addition, calling any Note for redemption will constitute a Make-Whole Fundamental Change with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption.

Holders of Notes may require the Company to repurchase their Notes upon the occurrence of certain events that constitute a fundamental change under the indenture governing the Notes at a fundamental change repurchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The following table summarizes the carrying value of the Notes at September 30, 2021 (in thousands):


		September 30, 2021		December 31, 2020
Gross proceeds	$	240,000	$	-
Unamortized debt discount		(6,814)		-
Carrying value	$	233,186	$	-

The following table summarizes the interest expense recognized related to the Notes for the three and nine months ended September 30, 2021 (in thousands):


		Three Months Ended		Nine Months Ended
		September 30, 2021		September 30, 2021
Stated interest	$	2,175	$	5,413
Amortized debt discount		316		792
Interest expense	$	2,491	$	6,205

Capped Call Transactions

Separately, the Company entered into privately negotiated capped call options with financial institutions. The capped call options cover, subject to customary anti-dilution adjustments, the number of shares of the Company’s common stock that initially underlie the Notes. The cap price of the capped call options is $10.70 per share, representing a premium of 100% above the closing price of $5.35 per share of the Company’s common stock on February 10, 2021, and is subject to certain adjustments under the terms of the capped call options. The capped call options, which have a final expiration date of February 11, 2027, are generally intended to reduce or offset potential dilution to the Company’s common stock upon conversion of the Notes with such reduction and/or offset, subject to a cap based on the cap price. The capped call transactions are separate transactions entered into by the Company, are not part of the terms of the Notes and will not change the holders’ rights under the Notes. Holders of the Notes will not have any rights with respect to the capped call options. The Company paid a total of $33.0 million in premiums for the capped call options,which was recorded as additional paid-in capital, using a portion of the gross proceeds from the issuance and sale of the Notes. The capped call options are excluded from diluted earnings per share because the impact would be anti-dilutive.

Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act.

On April 15, 2020, the Company received the proceeds from a loan in the amount of approximately $3.1 million (the “Loan”) from PNC Bank, National Association, as lender, pursuant to the Paycheck Protection Program (“PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). Under the CARES Act, loan forgiveness is available for the sum of eligible and documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the eight-week period beginning on the date of loan approval. On June 10, 2021, the loan was forgiven by the U.S. Small Business Administration (“SBA”). The Company has recorded the forgiven amount of the Loan of approximately $3.1 million as other income for the nine months ended September 30, 2021.

‎

Table of Contents

6. Financial Instruments

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy defines three levels and prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of ~~the~~ investments and is not a measure of ~~the~~ investment credit quality.

Items classified as Level 1 within the valuation hierarchy consist of the Company’s cash equivalents held in money market funds and its ownership of ~~MeiraGTx (Note 8).~~MeiraGTx. The Company measures these investments at fair value determined based on Level 1 observable quoted price market inputs.

Items classified as Level 2 within the valuation hierarchy consist of the Company’s marketable debt securities, warrant liabilities and ~~warrant liabilities.~~convertible notes. The Company estimates the fair values of the marketable debt securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The Level 2 inputs used to value the Company’s warrant liabilities were determined using prices that can be directly ~~observed or corroborated in active markets.~~observed. Although the fair value of this obligation is calculated using the observable market price of the Company’s common stock, an active market for this financial instrument does not exist.

~~Table~~ The fair value of ~~Contents~~

the Notes, which differs from their carrying value, is influenced by interest rates, stock price and stock price volatility and is determined by prices observed in market trading. The market for trading of the Notes is not considered to be an active market and therefore the estimate of fair value is based on Level 2 inputs. The estimated fair value of the Notes was approximately $348.3 million at September 30, 2021.

The following ~~tables present information about~~table presents the Company’s financial assets and liabilities that have been measured at fair value at September 30, ~~2020~~2021 and ~~indicates~~ the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):


				Fair Value Measurements Using									Fair Value Measurements Using

Description	Description	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Description	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Financial assets
Cash equivalents:
Money market funds		$	98,593	$	98,593	$	—	$	—		$	60,939	$	60,939	$	—	$	—
Corporate debt securities			2,823		—		2,823		—
Short-term investments:
Corporate debt securities			44,514		—		44,514		—			182,821		—		182,821		—
Ownership of MeiraGTx			9,238		9,238		—		—			9,196		9,196		—		—
		$	155,168	$	107,831	$	47,337	$	—		$	252,956	$	70,135	$	182,821	$	—

Financial liabilities
Warrant liabilities		$	1,016	$	—	$	1,016	$	—		$	3,408	$	—	$	3,408	$	—

The following table presents ~~information about~~ the Company’s financial assets and liabilities that have been measured at fair value at December 31, ~~2019~~2020 and ~~indicates~~ the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands):


				Fair Value Measurements Using									Fair Value Measurements Using
Description	Description	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)	Description	Total		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
Financial assets
Cash equivalents:
Money market funds		$	136,058	$	136,058	$	—	$	—		$	67,467	$	67,467	$	—	$	—
Corporate debt securities												3,041		—		3,041		—
Short-term investments:
Corporate debt securities												49,435		—		49,435		—
Ownership of MeiraGTx			41,997		41,997		—		—			10,564		10,564		—		—
		$	178,055	$	136,058	$	—	$	—		$	130,507	$	78,031	$	52,476	$	—

Financial liabilities
Warrant liabilities		$	1,485	$	—	$	1,485	$	—		$	1,082	$	—	$	1,082	$	—

The Company has not recognized any material gross realized gains or losses on sales of available-for-sale marketable debt securities.

Table of Contents

Ownership of MeiraGTx

The Company maintained a 1.6% ownership in the ordinary shares of MeiraGTx, a clinical-stage gene therapy company, with a fair value of $9.2 million and $10.6 million, at September 30, 2021 and December 31, 2020, respectively. The Company did not realize any gains in the three and nine months ended September 30, 2021, and realized gains of $4.2 million and $15.5 million for the three and nine months ended September 30, 2020, respectively, which represents the sale of 0.3 million and 1.1 million ordinary shares of MeiraGTx, respectively. The Company has recorded a net unrealized loss on its ownership of MeiraGTx ordinary shares of $1.6 million and $1.4 million for the three and nine months ended September 30, 2021, respectively, and net unrealized loss of $3.3 million and $32.8 million for the three and nine months ended September 30, 2020, respectively. The unrealized gain (loss) on equity securities consists of the change in unrealized gain or loss resulting from mark-to-market adjustments on equity securities still held. The Company’s ownership of MeiraGTx ordinary shares is valued using Level 1 inputs, which includes quoted prices in active markets for identical assets in accordance with the fair value hierarchy.

Warrant Liabilities

In connection with athe 2015 credit agreement, ~~entered into in 2015,~~ as fees to the lenders thereunder, the Company issued warrants to purchase an aggregate of $6.3 million of the Company’s Class A units with an expiration date of August 2022, which were exchanged for 617,651 warrants with a strike price of $10.20 per share to purchase the same number of shares of the Company’s common stock upon consummation of the Company’s IPO in August 2016 (the “2015 Warrants”).

As of September 30, ~~2020,~~2021, the exercise price of a portion of the 2015 Warrants to purchase an aggregate of 529,413 shares of the Company’s common stock was $3.30 per warrant share and the exercise price of the remaining 2015 Warrants to purchase an aggregate of 88,238 shares of the Company’s common stock was $4.50 per warrant share. Since these warrants are exercisable and are redeemable at the option of the holder upon the occurrence of, and during the continuance of, an event of default, the fair value of the 2015 Warrants was recorded as a short-term liability of approximately ~~$1.0~~$3.4 million at September 30, ~~2020~~2021 and approximately ~~$1.5~~$1.1 million at December 31, ~~2019.~~

~~Table of Contents~~

2020.

The Company used the Black-Scholes pricing model to value the ~~warrant~~ liability related to the 2015 Warrants at September 30, ~~2020~~2021 with the following assumptions: risk-free interest rate of 0.1%, expected term of ~~1.9~~0.9 years, expected volatility of ~~71.3%~~85.0% and a dividend rate of 0%. The change in fair value of the 2015 Warrants was approximately ~~$(0.6)~~$2.7 million and ~~$ (0.5)~~$2.3 million for the three and nine months ended September 30, ~~2020~~2021 and approximately ~~$0.1~~$(0.6) million and $(0.5) million for ~~both~~ the three and nine months ended September 30, ~~2019,~~2020, respectively. NaN of these instruments had been exercised as of September 30, ~~2020~~2021.

The table below represents a roll-forward of warrant liabilities measured using Level 2 inputs from January 1, ~~2020~~2021 to September 30, ~~2020~~2021 (in thousands):


	Significant Other Observable Inputs
	(Level 2)
Balance at January 1, ~~2020~~2021	$	~~1,485~~1,082
Change in fair value of warrant liabilities		~~(469)~~2,326
Balance at September 30, ~~2020~~2021	$	~~1,016~~3,408

The following table represents a roll-forward of warrants outstanding from January 1, ~~2020~~2021 to September 30, ~~2020:~~2021:

Warrants
Weighted Average
‎Exercise Price
Balance, January 1, 2020
11,921,452
$
5.97
Exercised
(4,400)
—
Balance, September 30, 2020
11,917,052
$
5.97



	Warrants	Weighted Average ‎Exercise Price
Balance, January 1, 2021	10,582,119	$	6.30
Exercised	(4,320,533)		3.35
Balance, September 30, 2021	6,261,586	$	8.34

Table of Contents

7. Inventories

Inventories are stated at the lower of cost or net realizable value (on a first-in, first-out basis) using standard costs. Standard costs include an allocation of overhead rates, which include those costs attributable to managing the supply chain and are evaluated regularly. Variances are expensed as incurred. The Company capitalizes inventory costs associated with the Company’s products after regulatory approval, if ever, when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. On July 16, 2021, REZUROCK received FDA approval and all subsequent inventory costs associated with REZUROCK are being capitalized. Raw materials and work-in-process include all inventory costs prior to packaging and labelling, including raw material, active product ingredient, and drug product. Finished goods include packaged and labelled products. The inventory balance as of September 30, 2021 does not include $0.1 million of inventory on hand that was previously expensed as research & development cost prior to FDA approval.

The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate. In addition, the Company’s product is subject to strict quality control and monitoring which the Company performs throughout the manufacturing process. If certain batches or units of product no longer meet quality specifications or the Company identifies excess, obsolete or unsalable inventory, its value is written down to net realizable value. Inventories recorded on the Company’s consolidated balance sheets are net of a reserve for expirable inventory of $2.6 million and $3.0 million at September 30, 2020 and December 31, 2019, respectively.

Inventories are comprised of the following (in thousands):



	September 30,		December 31,		September 30,		December 31,
	2020		2019		2021		2020
Raw materials	$	—	$	371	$	—	$	—
Finished goods, net		28		269		22		102
Total inventories, net	$	28	$	640	$	22	$	102

8. Fixed Assets

Fixed assets consisted of the following (in thousands):



	Useful Lives	September 30,		December 31,
	(Years)	2021		2020
Leasehold improvements	4-8	$	10,397	$	10,398
Office equipment and furniture	3-15		1,244		1,363
Machinery and laboratory equipment	3-15		3,963		3,835
Software	1-5		4,103		4,136
			19,707		19,732
Less accumulated depreciation and amortization			(18,822)		(18,445)
Fixed assets, net		$	885	$	1,287

Depreciation and amortization of fixed assets totaled $0.6 million and $1.3 million for the nine months ended September 30, 2021 and 2020, respectively, and $0.1 million and $0.5 million for the three months ended September 30, 2021 and 2020, respectively.

‎

1821

Table of Contents

~~7. Fixed Assets~~

~~Fixed assets consisted of the following (in thousands):~~

Useful Lives
September 30,
December 31,
(Years)
2020
2019
Leasehold improvements
Shorter of remaining lease term or useful life
$
10,397
$
10,397
Office equipment and furniture
3-7
1,363
1,234
Machinery and laboratory equipment
3-7
3,836
3,599
Software
3-5
4,089
3,971
Construction-in-progress
̶̶̶̶
—
45
19,685
19,246
Less accumulated depreciation and amortization
(18,065)
(16,802)
Fixed assets, net
$
1,620
$
2,444

Depreciation and amortization of fixed assets totaled $1.3 million and $1.4 million for the nine months ended September 30, 2020 and 2019, respectively, and $0.5 million for each of the three months ended September 30, 2020 and 2019.

~~8. Ownership of MeiraGTx Ordinary Shares~~

The Company maintained a 1.8% and 5.7% ownership in the ordinary shares of MeiraGTx with a fair value of $9.2 million and $42.0 million, at September 30, 2020 and December 31, 2019, respectively. The Company entered into transactions in July 2020 and May 2020 pursuant to which it sold approximately 0.3 million and 1.1 million ordinary shares of MeiraGTx, respectively, for gross proceeds of $4.2 million and $15.5 million, respectively, which was recorded as a realized gain on equity securities during the three and nine months ended September 30, 2020, respectively. The realized gain represents the total gain on the sale of ordinary shares since the MeiraGTx IPO in June 2018. The Company did not realize any gains in the three and nine months ended September 30, 2019. The Company has recorded a net unrealized (loss) gain on its ownership of MeiraGTx ordinary shares of $(3.3) million and $(38.6) million for the three months ended September 30, 2020 and 2019, respectively, and $(32.8) million and $22.3 million for the nine months ended September 30, 2020 and 2019, respectively. The unrealized gains on equity securities consists of two components: (i) the reversal of the gain or loss recognized in previous periods on equity securities sold and (ii) the change in unrealized gain or loss resulting from mark-to-market adjustments on equity securities still held. The Company’s ownership of MeiraGTx ordinary shares is valued using Level 1 inputs, which includes quoted prices in active markets for identical assets in accordance with the fair value hierarchy (Note 5).

~~The table below represents a rollforward of the Company’s ownership of MeiraGTx ordinary shares from January 1, 2020 to September 30, 2020 (in thousands):~~


	~~Significant Observable Inputs~~
	~~(Level 1)~~
~~Balance as of January 1, 2020~~	$	~~41,997~~
~~Unrealized loss on ordinary shares sold during the year~~		~~(8,244)~~
~~Realized gain on sale of ordinary shares~~		~~(19,784)~~
~~Unrealized loss on remaining ownership of ordinary shares~~		~~(4,731)~~
~~Balance as of September 30, 2020~~	$	~~9,238~~

The Company is party to a sublease agreement to provide office space to MeiraGTx, which is automatically renewed on a monthly basis unless MeiraGTx provides 30 days’ prior written notice. The Company recognized $0.1 million and $0.4 million to other revenue related to this sublease agreement during each of the three and nine months ended September 30, 2020 and 2019. The Company received cash payments of $0.4 million from MeiraGTx for each of the nine months ended September 30, 2020 and 2019 and had 0 amounts receivable from MeiraGTx at September 30, 2020 or December 31, 2019.

~~Table of Contents~~

9. License Agreements

The Company has entered into several license agreements for products currently under development. The Company’s license agreements are disclosed in the audited financial statements included in ~~Item 8~~“Note 11. License Agreements” of its Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020. Since the date of such financial statements, there have been no significant changes to the Company’s license ~~agreements other than described below.~~agreements.

~~Meiji~~Nano Terra, Inc.

~~In December 2019,~~On April 8, 2011, the Company entered into a ~~collaboration agreement~~series of transactions with ~~Meiji, a Tokyo-based wholly owned subsidiary of Meiji Holdings Co., Ltd., to form~~Nano Terra, Inc. (“Nano Terra”) and entered into a joint venture ~~to exclusively develop and commercialize belumosudil (KD025) in Japan and certain other Asian countries. The joint venture was entered into~~with Surface Logix, Inc. (“SLx”) (Nano Terra’s wholly-owned subsidiary) through the ~~creation~~formation of ~~Romeck Pharma,~~NT Life Sciences, LLC (“~~Romeck”~~NTLS”), ~~whereby the Company~~which had no material operations prior to 2021, and entered into a ~~royalty-bearing~~sub-licensing arrangement with NTLS and SLx. Pursuant to the sub-licensing arrangement, the Company was granted a worldwide, exclusive license ~~agreement with Romeck~~under certain intellectual property owned by SLx to three clinical-stage product candidates, including belumosudil, each of which were licensed by SLx to NTLS. NTLS is a research and ~~Meiji in exchange~~development company, which independently maintains intellectual property for the purpose of pursuing medical discoveries. The Company is represented on the board of managers of NTLS and is a ~~50% interest in Romeck. Romeck is domiciled in Japan with shared oversight between~~party to decisions which influence the ~~Company and Meiji. Under the terms~~direction of the license agreement, the Company received an upfront payment of $6.0 million in January 2020 and is eligible to receive an additional $23.0 million in development, regulatory and commercial milestone payments upon the occurrence of specified events over the term of the agreement. In addition, the Company is eligible to receive double-digit percentage royalty payments on sales of belumosudil (KD025) in Japan.organization.

The Company must pay to the previous shareholders of SLx from which Nano Terra acquired SLx, royalties on net sales in the amount of 5%. Additionally, after the 5% royalty has been paid, the Company must also pay royalties on the remaining net sales in the amount of 10% to NTLS. As the Company owns 50% of NTLS, the cumulative results of these obligations is that the Company will owe aggregate royalty payments totaling 9.75% on net sales of licensed products. The royalties will become due and recognizable at the time of sale and are payable to SLx and NTLS 45 calendar days after each quarter. All royalties paid to third parties are recorded as Cost of Sales in the Company’s consolidated financial statements. NTLS is required to distribute any royalties from belumosudil to the two parties (Kadmon and SLx) within 15 days of receipt as equity distributions.

Since inception, the Company has continuously assessed the applicability of FASB ASC 810, ~~Consolidation~~“Consolidation”, ~~to the aforementioned agreements and~~ based on the corporate structure, voting rights and contributions of the various parties in connection with these ~~agreements, determined that Romeck was a VIE, however consolidation was not required as~~agreements. The Company consolidates entities where the Company ~~was not~~has a direct or indirect controlling financial interest based on either a variable interest model or voting interest modeltity. As such, the Company will consolidate an entity that is concluded to be a variable interest entity (“VIE”) for which the Company is deemed to be the primary beneficiary ~~based upon~~and any entity in which the Company holds a majority voting interest or has majority ownership and control over the operational, financial and investing decisions of that entity.

With the approval of REZUROCK, NTLS has started to operationalize its structure and there was no activity of the joint venture prior to August 2021. NTLS does not meet any of the criteria for VIE classification, however, NTLS is subject to consolidation by the Company under the voting and managerial structure of the entity. The purpose of the VIE is to develop and commercialize belumosudil in Japan and the operations of Romeck will be financed entirely by Meiji. The Company has not and is not required to provide financial support under the agreements and has no exposure to loss as a result of its involvement in the VIE. The Company’s investment in Romeck was accounted for under the equity methodinterest model as the Company has majority control over the ability to exercise significant influence over Romeck. The equity method investment was recorded at immaterial cost representing the Company’s initial capital contribution for its ownership. This value was determined based upon the corporate structure which does not allocate profits or losses to the Company. An adjustment to this recorded investment will only occur upon a sales transaction or liquidation event, as defined in the agreement.

operational, financial and investing decisions of NTLS. The Company ~~evaluated~~controls the ~~arrangement under ASC 808,~~ ~~Collaborative Arrangements~~,board of managers of NTLS and ~~determined that the license agreement and related joint venture with Romeck is not within the scope of ASC 808, and that the license agreement represents a contract with a customer under ASC 606.~~any major operational decisions. The Company has ~~determined that the license agreement contains~~recorded a ~~single combined performance obligation that consists of the exclusive license to Kadmon’s intellectual property and related initial technology transfer. All other promises included~~noncontrolling interest in the ~~license agreement were deemed~~activity of NTLS based on its 50% ownership.

During the three and nine months ended September 30, 2021, the Company accrued royalties of approximately $0.6 million to ~~be immaterial~~SLx and approximately $1.2 million to NTLS related to net sales of REZUROCK. The royalties owed to SLx are recorded as accrued liabilities in the ~~context of the contract including clinical supply, participation in a JSC, and limited technical assistance as requested by Romeck and Meiji.~~

The Company determined that the $6.0 million non-refundable, upfront payment under the license agreement constituted the entire consideration to be included in the transaction price at the inception of the arrangement. As such, this amount was allocated to the single performance obligation. The potential development, regulatory and commercial milestone payments and sales-based royalties that the Company is eligible to receive represent variable consideration under the license agreement. The development and regulatory milestone amounts were excluded from the transaction price and were fully constrained based on their probability of achievement and the fact that Company cannot reasonably conclude that a significant reversal of revenue related to these milestones would not occur. Any future sales-based royalties, including commercial milestone payments based on the level of sales, will be included in the transaction price and recognized as revenue when the related sales occur and the milestones are achieved. The Company will reevaluate the transaction price at the end of each reporting period as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.

The single combined performance obligation represents a license of functional intellectual property. The Company had not received the upfront payment or completed the single combined performance obligation as of December 31, 2019. The Company recognized $6.0 million in license revenue in the first quarter of 2020 upon completion of the initial technology transfer. No other milestone or royalty revenues have been earnedconsolidated financial statements as of September 30, ~~2020.~~2021. As NTLS is consolidated, the Company has eliminated the $1.2 million and recorded a noncontrolling interest of approximately $0.6 million related to 50% of the net income of NTLS related to the royalties.

‎

2022

Table of Contents

10. Share-based Compensation

2016 Equity Incentive Plan

A total of ~~16,194,138~~21,785,738 shares of the Company’s common stock were authorized and reserved for issuance under the Company’s Amended and Restated 2016 Equity Incentive Plan (the “2016 Equity Plan”) at December 31, ~~2019.~~2020. On January 1, ~~2020,~~2021, pursuant to the evergreen provision contained in the 2016 Equity Plan, the number of shares reserved for future grants was increased by ~~5,591,600~~6,861,201 shares, which was ~~three and one half~~four percent ~~(3.5%~~(4%) of the outstanding shares of common stock on December 31, ~~2019.~~2020. This reserve will increase each subsequent anniversary through January 1, 2025, by an amount equal to the smaller of (a) 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by the Company’s board of directors. ~~At September 30, 2020, there were options to purchase an aggregate of 16,067,285 shares of common stock outstanding at a weighted average price of $5.28 per share~~

The following table summarizes share-based compensation expense under the 2016 Equity ~~Plan.~~Plan for the three and nine months ended September 30, 2021 and 2020.


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
General and administrative	$	2,554	$	1,745	$	8,115	$	4,916
Research and development		969		708		3,029		2,195
Total stock-based compensation expense	$	3,523	$	2,453	$	11,144	$	7,111

Total unrecognized compensation expense related to unvested options granted under the Company’s share-based compensation plan was ~~$14.0~~$26.0 million and ~~$6.5~~$11.9 million at September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively. That expense is expected to be recognized over a weighted average period of ~~2.1~~2.0 years and ~~2.2~~1.9 years as of September 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively. The Company recorded share-based compensation expense under the 2016 Equity Plan of $7.1 million and $5.6 million for the nine months ended September 30, 2020 and 2019, respectively, and $2.4 million and $1.5 million for the three months ended September 30, 2020 and 2019

The following table summarizes information about stock options outstanding, not including performance stock options, from January 1, ~~2020~~2021 to September 30, ~~2020:~~2021:



	Options Outstanding						Options Outstanding
	Number of Options	Weighted ‎Average ‎Exercise ‎Price		Weighted Average ‎Remaining ‎Contractual ‎Term (years)	Aggregate ‎Intrinsic ‎Value (in ‎thousands)		Number of Options	Weighted ‎Average ‎Exercise ‎Price		Weighted Average ‎Remaining ‎Contractual ‎Term (years)	Aggregate ‎Intrinsic ‎Value (in ‎thousands)
Balance, January 1, 2020	11,802,601	$	5.59	7.52	$	9,520
Balance, January 1, 2021							16,000,685	$	5.29	7.11	$	7,365
Granted	4,966,040		4.35				9,837,493		3.96
Exercised	(304,669)		3.13			411	(1,252,894)		3.72			2,019
Forfeited	(396,687)		4.70				(1,257,414)		5.25
Balance, September 30, 2020	16,067,285	$	5.28	7.47	$	5,322
Options vested and exercisable, September 30, 2020	8,706,640	$	6.29	6.10	$	4,105
Balance, September 30, 2021							23,327,870	$	4.81	7.69	$	99,960
Options vested and exercisable, September 30, 2021							10,496,431	$	5.83	6.08	$	39,287

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value calculated as the difference between the fair value of the Company’s common stock at September 30, ~~2020~~2021 ($~~3.92~~8.71 per share) and December 31, ~~2019~~2020 ($~~4.53~~4.15 per share) and the exercise price, multiplied by the related in-the-money options that would have been received by the option holders had they exercised their options at the end of the fiscal year. This amount changes based on the fair value of the Company’s common stock. There were 304,669 options exercised during the nine months ended September 30, 2020 with an aggregate intrinsic value of $0.4 million. There were 0 options exercised during the nine months ended September 30, 2019.

There were 4,966,040 stock options granted during the nine months ended September 30, 2020 with a weighted-average exercise price of $4.35. During the nine months ended September 30, 2019, 1,593,973 stock options were granted with a weighted-~~average exercise price of $2.23.~~ The fair value of each stock option award, not including performance stock options, was estimated at the date of grant using the Black-Scholes option-pricing model and the assumptions noted in the following table:



	Nine Months Ended	Nine Months Ended	Nine Months Ended	Nine Months Ended
	September 30, 2020	September 30, 2019	September 30, 2021	September 30, 2020
Options granted			9,837,493	4,966,040
Weighted average exercise price			$3.96	$4.35
Weighted average fair value of grants	$2.87	$1.48	$2.85	$2.87
Expected volatility	75.46% - 84.95%	76.19% - 77.73%	87.20% - 127.92%	75.46% - 84.95%
Risk-free interest rate	0.29% - 1.64%	1.41% - 2.61%	0.05% - 1.03%	0.29% - 1.64%
Expected life (years)	5.5 - 6.0	5.5 - 6.0	0.87 - 6.0	5.5 - 6.0
Expected dividend yield	0%	0%	0%	0%

2123

Table of Contents

Performance Options

A total of ~~1,290,000~~ 982,500 performance options (“Performance ~~Options~~Options”) with an exercise price of $4.06 were outstanding at September 30, ~~2020 with 0 intrinsic value and at December 31, 2019~~2021 with an intrinsic value of ~~$0.6~~$4.6 million and 1,290,000 at December 31, 2020 with an intrinsic value of $0.3 million. The weighted average remaining contractual life of outstanding Performance Options at September 30, ~~2020~~2021 was ~~5.4~~6.5 years. Compensation expense for Performance Options iswas recognized on a straight-line basis over the awards’ requisite service ~~period. At September 30, 2020, there was $0.1 million of total unrecognized compensation expense related to unvested Performance Options, which is expected to be recognized over a weighted-average~~ period of ~~0.5~~three years. At September 30, ~~2020 and December 31, 2019, 962,502 and 853,335~~2021, 1,290,000 Performance Options had vested ~~respectively,~~and 307,500 had been exercised. At December 31, 2020, 962,502 Performance Options had vested and 0 Performance Options had been exercised.

Stock Appreciation Rights

A total of ~~835,000~~655,000 stock appreciation rights (“SARs”) with an exercise price of $3.64 were outstanding at ~~both~~ September 30, ~~2020~~2021 and 835,000 at December 31, ~~2019~~2020 with an intrinsic value of ~~$0.2~~$3.3 million and ~~$0.7~~$0.5 million, respectively. The weighted average remaining contractual life of outstanding SARs at September 30, ~~2020~~2021 was ~~5.8~~6.2 years. Compensation expense for SARs iswas recognized on a straight-line basis over the awards’ requisite service period. At September 30, 2020, there was $0.1 million of total unrecognized compensation cost related to unvested SARs that is expected to be recognized over a weighted-average period of 0.2three years. At September 30, ~~2020~~2021, 835,000 SARs had vested and 180,000 had been exercised. At December 31, ~~2019, 616,667~~2020, 835,000 SARs had vested and 0 SARs had been exercised.

2014 Long-term Incentive Plan (the “LTIP”)

A total of 9,750 units have been granted under the LTIP as of both September 30, ~~2020~~2021 and December 31, ~~2019.~~2020. The LTIP is payable upon the fair market value of the Company’s common stock exceeding 333% of the $6.00 grant price (or $20.00) per share prior to December 7, 2024. The holders of the LTIP awards have no right to demand a particular form of payment, and the Company reserves the right to make payment in the form of cash or common stock. NaN LTIP awards were exercisable or had been exercised at September 30, ~~2020.~~2021.

2016 Employee Stock Purchase Plan

A total of 2,551,180 shares of the Company’s common stock were reserved for issuance under the Amended and Restated 2016 Employee Stock Purchase Plan (the “2016 ESPP”) at December 31, ~~2019.~~2020. The Company’s board of directors elected not to increase the shares reserved for issuance under the 2016 ESPP on January 1, ~~2020.~~2021. The Company issued ~~98,840~~94,420 and ~~32,273~~98,840 shares under the 2016 ESPP during the nine months ended September 30, ~~2020~~2021 and ~~2019,~~2020, respectively. NaN meaningful compensation expense was recognized for the ESPP during the three and nine months ended September 30, ~~2020~~2021 and ~~2019.~~ 2020.

11. Accrued Expenses

Short-term accrued expenses at September 30, ~~2020~~2021 and December 31, ~~2019~~2020 include the following (in thousands):



	September 30,		December 31,		September 30,		December 31,
	2020		2019		2021		2020
Commission payable	$	1,768	$	2,395
Compensation, benefits and severance		3,681		4,668
Compensation and benefits					$	4,937	$	5,585
Research and development		3,980		4,962		6,728		4,183
Interest						1,088		20
Other		783		2,223		2,485		1,746
Total accrued expenses	$	10,212	$	14,248	$	15,238	$	11,534

~~Commission payable~~

~~Commission payable represents commissions to third parties for Class E redeemable convertible unit raises during 2014~~Compensation and 2015. During the three and nine months ended September 30, 2020, the Company recorded $0.6 million as a non-cash gain on extinguishment of obligation due to the expiration of the Company’s obligation related to this portion of the commission.benefits

Compensation and benefits ~~and severance~~

~~Compensation, benefits and severance represent~~primarily represents earned and unpaid employee wages and ~~bonuses, as well as contractual severance to be paid to former employees.~~

~~Table of Contents~~

bonuses.

Research and development

The Company has contracts with third parties for the development of the Company’s product candidates. The timing of the expenses varies depending upon the timing of initiation of clinical trials and enrollment of patients in clinical trials.

~~Other~~Interest

~~During the three~~Interest represents accrued and ~~nine months ended September 30, 2020, the Company recorded $1.0 million as a non-cash gain~~unpaid interest on ~~extinguishment of obligation due to the expiration of~~ the Company’s ~~obligation relating to a terminated license agreement.~~outstanding indebtedness (Note 5).

‎

Table of Contents

12. Commitments and Contingencies

The Company’s commitments are disclosed in the audited financial statements included in ~~Item 8~~“Note 15. Commitments and Contingencies” of the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020. Since the date of such financial statements, there have been no material changes to the Company’s commitments or contingencies, including ~~leases.~~leases, other than the legal proceedings described below.

Contingent License Agreement Milestones

The Company has entered into several license agreements for products currently under development (Note 9). The Company may be obligated in future periods to make additional payments, which would become due and payable only upon the achievement of certain research and development, regulatory and approval milestones. The specific timing of such milestones cannot be predicted and depends upon future discretionary clinical developments as well as regulatory agency actions which cannot be predicted with certainty (including action which may never occur). These additional contingent milestone payments aggregate to $229.1 million at September 30, ~~2020.~~2021. Any payments made prior to FDA approval will be expensed as research and development. ~~Payments~~Any payments made after FDA approval will be capitalized.

Under the terms of certain licensing agreements, the Company may be obligated to pay commercial milestones contingent upon the realization of sales revenues and sublicense revenues. Due to the long-range nature of such commercial milestones, they are neither probable at this time nor predictable, and consequently are not included in the additional contingent milestone payment amount.

~~13. Related Party Transactions~~Legal Proceedings

The ~~Company’s related party transactions are disclosed~~Company is subject to various legal proceedings that arise from time to time in the ~~audited financial statements~~ ~~included~~ordinary course of its business. Although the Company believes that the various proceedings brought against it are without merit, and that it has adequate product liability and other insurance to cover any claims, litigation is subject to many factors which are difficult to predict and there can be no assurance that the Company will not incur material costs in ~~Item 8~~the resolution of legal matters. Should the Company determine that any future obligations will exist, the Company will record expense equal to the amount which is deemed probable and estimable.

GoldenTree Master Fund, Ltd. v. Kadmon Holdings, Inc.

On April 21, 2021, GoldenTree Master Fund, Ltd (“GoldenTree”) filed suit in the Supreme Court of New York bringing claims for breach of contract, unjust enrichment, and fraudulent inducement. On October 18, 2021, the Supreme Court of New York signed a stipulation filed by the parties whereby the parties have agreed, subject to certain terms and conditions, that this suit should be stayed in its entirety pending the outcome of the ~~Company’s Annual Report on Form 10-K~~vote of Kadmon stockholders to approve or disapprove the Sanofi Merger, and that the action should be voluntarily discontinued upon approval and closing of the Sanofi Merger and the cancellation of the preferred shares in exchange for the ~~year ended December 31, 2019. Since~~applicable Liquidation Value as defined in the ~~date~~applicable Certificate of ~~such financial statements, there have been no changes to~~Designations of the ~~Company’s related party transactions other than those related to MeiraGTx (Note 8).~~securities that form the subject matter of the dispute.

~~14.~~
‎

Table of Contents

13. Income Taxes

The Company files a consolidated tax return for Kadmon Holdings, Inc. and its domestic subsidiaries and the required information returns for its international subsidiaries, all of which are wholly owned. Where permitted, the Company files combined state returns, but in some instances separate company returns for certain subsidiaries on a stand-alone basis are required.

There was 0 change in deferred tax liability and no0 income tax expense recorded for the three and nine months ended September 30, ~~2020~~2021 and ~~2019.~~2020. Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss (“NOL”) carryforwards and other balance sheet basis differences. In accordance with ASC 740, Income Taxes, the Company recorded a valuation allowance to fully offset the gross deferred tax asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets at September 30, ~~2020~~2021 and December 31, ~~2019.~~ 2020.

At December 31, ~~2019,~~2020, the Company had unused federal and state NOL carryforwards of ~~$371.1~~$408.4 million and ~~$307.2~~$349.6 million, respectively, that may be applied against future taxable income. The Company has fully reserved the deferred tax asset related to these NOL carryforwards as reflected in its consolidated financial statements. ~~These~~Approximately $291.1 million of the federal NOL carryforwards expire at various dates through December 31, 2037, ~~with the exception of~~and approximately ~~$79.9~~$117.3 million of federal ~~NOL~~net operating loss carryforwards ~~that~~ will not expire.Approximately all of the $349.6 million state NOL carryforwards expire at various dates through December 31, 2040.

14. Subsequent Events

Legal Proceedings

Between October 1 and October 26, 2021, ten alleged stockholders of the ~~United States, President Trump signed into law~~Company filed actions in federal courts located in the ~~CARES Act~~states of New York, Delaware, and Pennsylvania against the Company and the members of its Board of Directors under the following captions: (i) Nancy Jaser v. Kadmon Holdings, Inc., et al., No. 1:21-cv-08154 (S.D.N.Y.); (ii) John Dillon v. Kadmon Holdings, Inc., et al., No. 1:21-cv-08169 (S.D.N.Y.); (iii) Alex Ciccotelli v. Kadmon Holdings, Inc., et al., No. 1:21-cv-08299 (S.D.N.Y.); (iv) Michael Young v. Kadmon Holdings, Inc., et al., No. 1:21-cv-05641 (E.D.N.Y.); (v) Michael Bierman v. Kadmon Holdings, Inc., et al., No. 1:21-cv-08441 (S.D.N.Y.); (vi) Jacob Wheeler v. Kadmon Holdings, Inc., et al., No. 1:21-cv-08576 (S.D.N.Y.); (vii) Robert Wilhelm v. Kadmon Holdings, Inc., et al., No. 1:21-cv-01470 (D. Del.); (viii) Matthew Whitfield v. Kadmon Holdings, Inc., et al., No. 2:21-cv-04605 (E.D. Pa.); (ix) Jerome Anderson v. Kadmon Holdings, Inc., et al., No. 1:21-cv-08705 (S.D.N.Y.); and (x) Joseph Gibson v. Kadmon Holdings, Inc., et al., No. 1:21-cv-01503 (D. Del.) (collectively, the “Merger Actions”). The Merger Actions assert claims solely on ~~March 27, 2020, which provides relief~~behalf of the individual stockholders and generally allege that the Company and its Board of Directors failed to ~~taxpayers affected~~disclose allegedly material information in the definitive proxy statement on Schedule 14A filed with the SEC on October 4, 2021. The Merger Actions seek an order enjoining the consummation of the transactions contemplated by ~~COVID-19. The CARES Act includes several business provisions that may impact a company’s accounting for income taxes. In addition,~~ the ~~impact of COVID-19 itself on businesses draws attention to certain provisions in ASC 740.~~Merger Agreement and awarding damages. The Company ~~analyzed~~believes that the ~~business provisions~~claims asserted in the ~~CARES Act and determined that the Act does not have a significant impact on its income tax provision.~~Merger Actions are without merit.

2326

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires, references to the “Company,” “Kadmon,” “we,” “us” and “our” refer to Kadmon Holdings, Inc. and its consolidated subsidiaries. You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing in this Quarterly Report on Form 10-Q and those in included in Item 8 of our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” and “Forward-Looking Statements” sections of this Quarterly Report on Form 10-Q ~~(including in the section titled “Forward-Looking Statements”)~~ and our most recent Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.

Overview

We are a ~~clinical-stage~~ biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address significant unmet medical needs. Our clinical pipeline includes developmental treatments for immune and fibrotic diseases as well as immuno-oncology therapy candidates. We leverage our multi-disciplinary research and development team members to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We believe that we have the ability to progress these candidates ourselves while maintaining flexibility for commercial and licensing arrangements. We expect to continue to progress our clinical candidates and have further clinical trial and regulatory events to report in the remainder of 2020 and in 2021.therapies.

The Company’s most advanced product candidate, belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (“ROCK2”), a signaling pathway that modulates inflammatory response. The Company is initially developing belumosudil for the treatment of chronic graft-versus-host disease (“cGVHD”), an immune-mediated inflammatory and fibrotic disorder. On September 30, 2020, the Company submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for belumosudil for the treatment of patients with cGVHD. The NDA is subject to acceptance by the FDA. The NDA is being reviewed under the Real-Time Oncology Review (“RTOR”) pilot program, an initiative of the FDA's Oncology Center of Excellence (“OCE”). The RTOR program aims to explore a more efficient review process to ensure that safe and effective treatments are available to patients as early as possible.

The NDA submission is supported by positive data observed in ROCKstar (KD025-213), the Company’s pivotal clinical trial evaluating belumosudil in 132 patients with cGVHD who have received two or more prior lines of systemic therapy. As previously reported, belumosudil achieved clinically meaningful and statistically significant Overall Response Rates of 73% with 200 mg once daily and 74% with 200 mg twice daily. Responses were achieved across key patient subgroups and complete responses were observed in all organ systems. Belumosudil has been well tolerated and adverse events have been consistent with those expected in the patient population.

The FDA has granted Orphan Drug Designation to belumosudil for the treatment of cGVHD, and the FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD after failure of two or more lines of systemic therapy.

The recent global pandemic caused by a novel strain of the coronavirus SARS-COV-2, which causes a disease that is referred to as coronavirus disease 2019 (“COVID-19”), may materially affect us economically. While the economic impact of the COVID-19 pandemic may be difficult to assess or predict, this widespread pandemic has resulted in a significant disruption of global financial markets, which may reduce our ability to access capital. If the disruption to the financial markets is protracted, our liquidity could be negatively affected in the future. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock. During these uncertain times, the Company’s top priorities are to ensure the health and welfare of its employees, maintain product safety and continue to advance its clinical studies. However, our clinical trials have been impacted, and we may experience delays in anticipated timelines and milestones. For instance, due to interruptions at clinical sites, enrollment has been delayed in our ongoing Phase 2 clinical trial of belumosudil in systemic sclerosis and enrollment was also delayed in our ongoing Phase 1 clinical trial of KD033 in patients with metastatic or locally advanced solid tumors. In addition, we may experience disruptions in our supply chain, including our supply of our product candidates, which may adversely affect the conduct of our clinical trials. We rely on contract research organizations (“CROs”) to conduct our clinical trials. Our CROs may be unable to conduct clinical trials for product candidates as a result of the COVID-19 pandemic. The COVID-19 pandemic could impact our healthcare systems and our clinical trial sites’ ability to conduct trials to varied degrees and times. COVID-

~~Table of Contents~~

~~19 creates risk of interrupting availability of necessary clinical supplies as well as local regulatory reviews, hospital ethics committee reviews and site monitors.~~

Our operations to date have been focused on developing first-in-class innovative therapies for indications with significant unmet medical needs while leveraging our commercial infrastructure. We believe that we have the ability to progress these candidates ourselves while maintaining flexibility for commercial and licensing arrangements. In addition to these discovery and development efforts, our business strategy includes the efficient commercialization of these drugs in the U.S. and certain other regions upon regulatory approval. By focusing on rare disease markets, we believe that we can more effectively control the costs of, and our strategic allocation of financial resources toward, post-approval commercialization.

Our revenues are difficult to predict and depend on several factors. For example, our revenues depend, in part, on regulatory approval decisions for our product and product candidates, the effectiveness of our and our collaborative partners’ commercialization efforts, market acceptance of our products, particularly REZUROCK™ (belumosudil), the resources dedicated to our products and product candidates by us and our collaborative partners, and our ability to enter into or modify licensing agreements for our product candidates. We have never been profitable and had an accumulated deficit of ~~$415.7~~$538.1 million at September 30, ~~2020.~~2021.

~~Although~~Our operating expenses are also difficult to predict and depend on several factors, including commercialization expenses, research and development expenses, drug manufacturing, and clinical research activities, the ongoing requirements of our ~~commercial business generates revenue through~~development programs and the ~~sale~~availability of ~~CLOVIQUE™ (Trientine Hydrocholride), the revenues generated~~capital. As our commercialization activities for ~~the three~~REZUROCK and ~~nine months ended September 30, 2020~~research and ~~2019 were not significant, and~~development programs continue to advance, we expect our operating costs will increase. Management may be able to ~~incur significant~~control the timing and level of research and development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.

As a result of these factors, we believe that period-to-period comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance. The Company has sustained operating losses for the ~~foreseeable future~~majority of its corporate history and ~~expect these~~the Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to ~~increase as we continue our development~~support ongoing operations. Due to all of ~~and seek regulatory approvals for, our additional product candidates, hire additional personnel and initiate commercialization of any products that receive regulatory approval. We anticipate~~the foregoing factors, it is possible that our ~~expenses~~operating results will ~~increase substantially if, or~~be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.

Recent Corporate Highlights

Pending Acquisition by Sanofi

On September 7, 2021, Kadmon entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanofi, a French société anonyme (“Sanofi”), and Latour Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Sanofi (“Merger Subsidiary”), providing for the merger of Merger Subsidiary with and into the Company (the “Merger”), with the Company surviving the Merger as ~~we:~~a wholly owned subsidiary of Sanofi (the “Parent”). Capitalized terms not otherwise defined in this section “Pending Acquisition by Sanofi” have the meanings set forth in the Merger Agreement.

‎

Table of Contents

~~invest significantly~~each share of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”) issued and outstanding as of immediately prior to ~~further develop our most advanced product candidates;~~the Effective Time (other than Dissenting Shares, Company Common Stock held by the Company as treasury stock or owned by Parent, Merger Subsidiary or any Subsidiary of the Company or Parent) will be cancelled and cease to exist and automatically convert into the right to receive cash in an amount equal to $9.50, without interest (the “Common Stock Merger Consideration”);

~~initiate clinical trials~~each share of 5% convertible preferred stock, par value $0.001 per share, of the Company (“Company Preferred Stock”) issued and ~~preclinical studies for our other product candidates;~~outstanding as of immediately prior to the Effective Time (other than Dissenting Shares) will be cancelled and cease to exist and automatically convert into the right to receive cash in an amount equal to the greater of (i) the Stated Liquidation Preference Amount (as defined in the Company’s Certificate of Designation dated July 26, 2016) plus any dividends (whether or not earned or declared) accrued and unpaid thereon from the last Dividend Payment Date (as defined in the Certificate of Designation) through the closing date of the Merger and (ii) the amount that would be payable per share of Company Preferred Stock if such share of Company Preferred Stock had been converted to Company Common Stock immediately prior to the effective time of the Merger (the “Preferred Stock Merger Consideration”);

~~seek regulatory approval for~~all unvested options to purchase Company Common Stock (“Company Options”) which are outstanding immediately prior to the Effective Time will fully vest and become exercisable and, to the extent not exercised prior to the Effective Time, be canceled at the Effective Time with the former holder of such canceled Company Option becoming entitled to receive an amount in cash (without interest and subject to any applicable withholding or other taxes, or other amount as required by law) equal to (1) the number of shares of Company Common Stock subject to such Company Option multiplied by (2) the excess, if any, of ~~our product candidates~~the Common Stock Merger Consideration over the exercise price per share of such Company Option; provided that ~~successfully complete clinical trials;~~each Company Option with an exercise price per share equal to or greater than the Common Stock Merger Consideration will be canceled without consideration;

~~continue~~all unvested stock appreciation rights granted by the Company (“Company SARs”) which are outstanding as of immediately prior to ~~invest~~the Effective Time will fully vest and, to the extent not exercised prior to the Effective Time, be canceled at the Effective Time, with the former holder of such canceled Company SAR becoming entitled to receive an amount in ~~our research discovery platforms;~~cash (without interest and subject to any applicable withholding or other taxes, or other amount as required by law) equal to (A) the excess, if any, of the Common Stock Merger Consideration over the exercise price per share of such Company SAR multiplied by (B) the number of shares of Company Common Stock underlying such Company SAR; provided that each Company SAR with an exercise price per share equal to or greater than the Common Stock Merger Consideration will be canceled without consideration; and

~~seek~~all unvested equity appreciation rights granted by the Company (“Company EARs”) which are outstanding as of immediately prior to ~~identify~~the Effective Time will fully vest and ~~develop additional product candidates;~~be canceled at the Effective Time, with the former holder of such canceled Company EAR becoming entitled to receive an amount in cash (without interest and subject to any applicable withholding or other taxes, or other amount as required by law) equal to (A) the excess of the Common Stock Merger Consideration over the base price per share of such Company EAR multiplied by (B) the number of shares of Common Stock underlying such Company EAR; provided that each Company EAR with a base price per share equal to or greater than the Common Stock Merger Consideration will be canceled without consideration.

~~scale up our sales, marketing~~Consummation of the Merger is subject to customary closing conditions, including, without limitation, the absence of certain legal impediments, the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and ~~distribution infrastructure~~approval by the holders of a majority of the voting power of the outstanding shares of Company Common Stock and ~~product sourcing capabilities;~~Company Preferred Stock, voting on an as converted to Company Common Stock basis, entitled to vote on such matter.

The Company has made representations and warranties in the Merger Agreement and has agreed to covenants regarding the operation of the business of the Company and the Company Subsidiaries prior to the Effective Time. The Company is also subject to customary restrictions on its ability to solicit alternative acquisition proposals from third parties and to provide non-public information to, and participate in discussions and engage in negotiations with, third parties regarding alternative acquisition proposals. The Merger Agreement also contains customary covenants requiring the Board, subject to certain exceptions, to recommend that the Company’s stockholders approve the Merger. Prior to the approval of the Merger by the Company’s stockholders, the Board may withhold, withdraw, qualify, or modify its recommendation that the Company’s stockholders approve the Merger because of a Company Intervening Event or may adopt, approve or recommend any Superior Proposal, subject to complying with notice and other specified conditions.~~acquire or in-license other product candidates and technologies;~~
‎

Table of Contents

~~scale up our operational, financial~~The Merger Agreement contains certain termination rights for both the Company and ~~management information systems~~Parent, including that, subject to certain limitations, (i) the Company or Parent may terminate the Merger Agreement if the Merger is not consummated by March 7, 2022, (ii) the Company and ~~personnel, including personnel~~Parent may mutually agree to ~~support our product development;~~terminate the Merger Agreement, (iii) the Company may terminate the Merger Agreement to accept a Superior Proposal and (iv) Parent may terminate the Merger Agreement because the Board changes its recommendation to the Company stockholders with respect to approval of the Merger.

~~make milestone~~The Company will be required to pay a termination fee of $60.1 million in the event that the Company terminates the Merger Agreement to accept a Superior Proposal or ~~other payments~~if Parent terminates the Merger Agreement because the Board changes its recommendation to the Company’s stockholders to approve the Merger. In addition, the Company will be required to pay the termination fee under ~~any in-license agreements;~~specified circumstances if, within 12 months after the termination of the Merger Agreement, the Company enters into or consummates a Competing Acquisition Transaction.

~~maintain, expand~~The foregoing description of the Merger Agreement and ~~protect~~the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Merger Agreement, which is attached as an exhibit to our ~~intellectual property portfolio.~~ Current Report on Form 8-K filed with the SEC on September 8, 2021 and incorporated herein by reference.

~~Components of Statement of Operations~~COVID-19 Update

The ~~components~~ongoing COVID-19 pandemic has severely impacted global economic activity and caused significant volatility in financial markets. While our financial condition, results of operations, cybersecurity and liquidity have not been materially impacted by the direct effects of the pandemic, the COVID-19 pandemic continues to evolve. We are continuing to monitor developments with respect to the COVID-19 pandemic and to make adjustments as needed to assist in protecting the safety of our ~~statement~~employees and communities while continuing our business activities. To date, implementation of these measures has not required material expenditures or significantly impacted our ability to operate our business or our internal control over financial reporting and disclosure controls and procedures. We are continuing to monitor the potential impacts of COVID-19 on our operations ~~are disclosed~~and those of our partners, suppliers, customers, and regulators, including commercial and clinical drug supply chain continuity and commercial launch of REZUROCK.

Notwithstanding the foregoing, we cannot precisely predict the impact that the COVID-19 pandemic will have in the ~~audited financial statements for~~future due to numerous uncertainties, including the ~~year ended December 31, 2019~~severity of the disease and its variants, the duration of the pandemic, actions that may be taken by governmental authorities, the impact to the business of potential variations or disruptions in our supply chain, and other factors identified in Part I, Item 1A. “Risk Factors” included in our Annual Report on Form 10-K ~~filed~~for the year ended December 31, 2020. We will continue to closely monitor and evaluate the nature and extent of the impact of the COVID-19 pandemic to our business, consolidated results of operations, and financial condition.

REZUROCK^™ (belumosudil)

REZUROCK is an oral tablet developed by Kadmon for the treatment of cGVHD. REZUROCK was approved by the FDA on ~~March 5, 2020~~July 16, 2021 for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy. REZUROCK was made available in the ~~Securities Exchange Commission (“SEC”). Since~~United States in August 2021.

We began generating revenue from sales of REZUROCK in the ~~date~~third quarter of ~~such financial statements, there have been no significant changes~~2021. Revenue from sales of REZUROCK in future periods is subject to uncertainties and will depend on several factors, including the ~~components~~success of our ~~statement~~and our partners’ commercialization efforts in the U.S., the number of ~~operations.~~new patients switching to REZUROCK, patient retention and demand, the number of physicians prescribing REZUROCK, the rate of monthly prescriptions, reimbursement from third-party payors, the conversion of patients from our clinical trials to commercial customers, and market trends. We will monitor and analyze this data during the initial launch period.

Financial Outlook for 2022

In the launch period for REZUROCK, expected to be through 2022, the Company is not providing specific revenue or operating guidance. Based on our expectations for revenue and operating expenses, we believe our current cash runway takes us into 2023.

Table of Contents

Critical Accounting Policies ~~and Significant Judgments~~ and Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with ~~accounting principles~~U.S. generally accepted ~~in the United States of America~~accounting principles (“GAAP”). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reporting amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. ~~On an ongoing~~We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee. In particular, we routinely evaluate our estimates and ~~judgments, including those related to~~policies regarding revenue recognition, share-based compensation and the accrual of research and development and clinical trial ~~expenses and the valuation of our ownership of MeiraGTx Holdings plc (“MeiraGTx”) ordinary shares.~~expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

~~Critical Accounting Policies~~

~~Our~~See our significant accounting policies ~~are~~ disclosed in “Note 2. Summary of Significant Accounting Policies” in our audited financial statements for the year ended December 31, ~~2019~~2020 included in our Annual Report on Form 10-K ~~filed on March 5, 2020 with~~for a description of accounting policies that we believe are the ~~SEC.~~ most critical to aid you in fully understanding and evaluating our reported financial results and that affect the more significant judgments and estimates that we use in the preparation of our financial statements. Since the date of such financial statements, there have been no changes to our significant accounting policies other than those described in Note 2 of the notes to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Recent Accounting Pronouncements

See Note 2 of the notes to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a summary of recently issued and adopted accounting pronouncements.

‎

2530

Table of Contents

Results of Operations

Three and ~~Nine Months Ended~~nine months ended September 30, ~~2020~~2021 and ~~2019~~

2020



	Three Months Ended				Nine Months Ended				Three Months Ended				Nine Months Ended
	September 30,				September 30,				September 30,				September 30,
	2020		2019		2020		2019		2021		2020		2021		2020
	(unaudited)								(unaudited)
	(in thousands)								(in thousands)
Revenues
Net sales	$	339	$	50	$	1,227	$	164	$	12,223	$	339	$	12,607	$	1,227
Other revenue		151		176		6,446		529		2,483		151		2,859		6,446
Total revenue		490		226		7,673		693		14,706		490		15,466		7,673
Cost of sales		214		73		704		149		643		214		750		704
Write‑down of inventory		148		—		1,054		932
Write-down of inventory										—		148		—		1,054
Gross profit		128		153		5,915		(388)		14,063		128		14,716		5,915
Operating expenses:
Research and development		17,268		13,227		46,658		43,326		18,850		17,268		52,649		46,658
Selling, general and administrative		10,865		10,174		30,299		27,101		21,599		10,865		47,852		30,299
Total operating expenses		28,133		23,401		76,957		70,427		40,449		28,133		100,501		76,957
Loss from operations		(28,005)		(23,248)		(71,042)		(70,815)		(26,386)		(28,005)		(85,785)		(71,042)
Total other income (expense)		3,399		(39,147)		(10,013)		21,172
Total other (expense) income										(6,657)		3,399		(5,981)		(10,013)
Income tax expense		—		—		—		—		—		—		—		—
Net loss	$	(24,606)	$	(62,395)	$	(81,055)	$	(49,643)	$	(33,043)	$	(24,606)	$	(91,766)	$	(81,055)
Deemed dividend on convertible preferred stock		543		517		1,578		1,540
Less: Net income attributable to noncontrolling interest										580		—		580		—
Less: Deemed dividend on convertible preferred stock										571		543		1,657		1,578
Net loss attributable to common stockholders	$	(25,149)	$	(62,912)	$	(82,633)	$	(51,183)	$	(34,194)	$	(25,149)	$	(94,003)	$	(82,633)

Revenues

The increase in total revenue for the three and nine months ended September 30, 2021 as compared to the three and nine months ended September 30, 2020 was primarily attributable to FDA approval of REZUROCK in the third quarter of 2021 resulting in net sales of $12.2 million. The decrease in other revenue for the nine months ended September 30, 2021, as compared to the nine months ended September 30, ~~2019~~2020 was primarily attributable to a $6.0 million milestone payment earned in the first quarter of 2020 pursuant to a joint venture and license agreement entered into with Meiji Seika Pharma Co., Ltd ~~(“Meiji”)~~ to develop belumosudil ~~(KD025)~~ in Japan. ~~The increase in net sales~~Other revenue for the three and nine months ended September 30, ~~2020 as compared~~2021 includes a $2.0 million milestone payment earned pursuant to ~~the three and nine months ended September 30, 2019 was due~~a strategic partnership with BioNova Pharmaceuticals Ltd. to ~~an increase~~develop belumosudil (KD025) in ~~CLOVIQUE sales.~~China.

Cost of ~~sales~~Sales and inventory write-down ~~of inventory~~

The increase in cost of sales for the three and nine months ended September 30, ~~2020~~2021 as compared to the three and nine months ended September 30, ~~2019,~~2020 was primarily attributable to the increase in ~~CLOVIQUE~~REZUROCK net sales revenue.

The inventory ~~write-downs~~write-down during the three and nine months ended September 30, 2020 ~~and 2019~~ related to write-downs of our CLOVIQUE inventory based on our expectation that such inventory will not be sold prior to reaching its product expiration date.

Research and development expenses

The increase in research and development expenses for the three and nine months ended September 30, ~~2020~~2021 as compared to the three and nine months ended September 30, ~~2019~~2020 was primarily related to an increase in ~~development~~direct external costs ~~for belumosudil.~~of developing our preclinical product candidates from our immuno-oncology platform.

Selling, general and administrative expenses

The increase in selling, general and administrative expenses for the three and nine months ended September 30, 2021 as compared to the three and nine months ended September 30, 2020 ~~as compared to the nine months ended September 30, 2019~~ was primarily attributable to increased expenses related to the ~~preparation for the potential~~ launch of ~~belumosudil.~~REZUROCK, as well as employee stock compensation and certain fees related to the pending acquisition with Sanofi.

2631

Table of Contents

Total other (expense) income ~~(expense)~~

The following table provides components of other ~~income~~ (expense): income:

Three Months Ended
Nine Months Ended
September 30,
September 30,
2020
2019
2020
2019
(unaudited)
(unaudited)
(in thousands)
(in thousands)
Interest income
$
208
$
418
$
802
$
1,622
Interest expense
(8)
(836)
(13)
(2,516)
Amortization of debt discount
—
(95)
—
(283)
Change in fair value of warrant liabilities
602
(126)
469
(70)
Realized gain on equity securities
4,274
—
19,784
—
Unrealized (loss) gain on equity securities
(3,254)
(38,634)
(32,759)
22,304
Gain on extinguishment of obligation
1,626
—
1,754
—
Other (expense) income
(49)
126
(50)
115
Total other income (expense)
$
3,399
$
(39,147)
$
(10,013)
$
21,172



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
	(unaudited)				(unaudited)
	(in thousands)				(in thousands)
Interest income	$	1,246	$	208	$	2,966	$	802
Interest expense		(2,492)		(8)		(6,218)		(13)
Unrealized loss on equity securities		(1,619)		(3,254)		(1,368)		(32,759)
Realized gain on equity securities		—		4,274		—		19,784
Gain on extinguishment of obligations		—		1,626		458		1,754
PPP loan forgiveness		—		—		3,091		—
Change in fair value of warrant liabilities		(2,674)		602		(2,326)		469
Other expense		(1,118)		(49)		(2,584)		(50)
Total other (expense) income	$	(6,657)	$	3,399	$	(5,981)	$	(10,013)

The ~~change~~decrease in other ~~income (expense)~~expense for ~~the three and~~ nine months ended September 30, ~~2020~~2021 as compared to ~~other income for the three and~~ nine months ended September 30, ~~2019~~2020 was primarily attributable to the fluctuations in our ownership of MeiraGTx ordinary ~~shares.~~

shares and PPP loan forgiveness in June 2021 of approximately $3.1 million, offset by the increase in interest expense related to our convertible notes issued in February 2021. The increase in other expense for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020 was primarily attributable to the fluctuations in our ownership of MeiraGTx ordinary shares and other financial instruments.

Deemed dividend on convertible preferred stock

We have 28,708 shares of 5% convertible preferred stock outstanding at September 30, 2021, which accrue dividends at a rate of 5% and convert into shares of our common stock at a 20% discount to the initial public offering price per share of common stock in our IPO of $12.00 per share, or $9.60 per share. ~~In May 2019, the holders of 1,292 shares of 5% convertible preferred stock exercised their right to convert their convertible preferred shares into 154,645 shares of our common stock.~~ The stated liquidation preference amount on the 5% convertible preferred stock totaled ~~$34.8~~$36.5 million at September 30, ~~2020.~~2021.

‎

Table of Contents

Liquidity and Capital Resources

Sources of Liquidity

Since our inception through September 30, ~~2020,~~2021, we have raised net proceeds from the issuance of equity and debt. We maintained cash, cash equivalents and marketable debt securities of ~~$150.5~~$251.6 million at September 30, ~~2020.~~ 2021. We expect that our cash, cash equivalents and marketable debt securities as of September 30, 2021 will enable us to fund our operating expenses and capital expenditure requirements into 2023, based on our current business plan.

The following table sets forth the primary sources and uses of cash, cash equivalents and restricted cash for each period set forth below:

Nine Months Ended
September 30,
2020
2019
(unaudited)
(in thousands)
Net cash provided by (used in):
Operating activities
$
(61,129)
$
(63,947)
Investing activities
(25,168)
(430)
Financing activities
52,650
35,769
Net decrease in cash, cash equivalents and restricted cash
$
(33,647)
$
(28,608)



	Nine Months Ended
	September 30,
	2021		2020
	(unaudited)
	(in thousands)
Net cash (used in) provided by:
Operating activities	$	(80,380)	$	(61,129)
Investing activities		(136,293)		(25,168)
Financing activities		211,076		52,650
Net decrease in cash, cash equivalents and restricted cash	$	(5,597)	$	(33,647)

~~Table of Contents~~

Operating Activities

The net cash used in operating activities was $80.4 million for the nine months ended September 30, 2021, and consisted primarily of a net loss of $(91.8) million adjusted for $18.1 million in net non-cash items, primarily including share-based compensation expense of $11.1 million and depreciation and amortization of fixed assets and noncash operating lease cost of $3.4 million, as well as a net increase in operating assets and liabilities of $6.7 million. Once adjusted for the non-cash items above, the cash used in operating activities for the nine months ended September 30, 2021 was primarily driven by selling, general and administrative expenses of $36.6 million and research and development expense of $49.6 million related to the advancement of our clinical product candidates.

The net cash used in operating activities was $61.1 million for the nine months ended September 30, 2020, and consisted primarily of a net loss of $(81.1) million adjusted for $22.8 million in net non-cash items, including unrealized loss on equity securities of $13.0 million, change in fair value of warrant liabilities of $(0.5) million, gain on ~~extinguishment~~settlement of obligation of $(1.8) million and share-based compensation expense of $7.1 million, offset by the depreciation and amortization of fixed assets and noncash operating lease cost of $3.9 million and write-down of inventory of $1.1 million, as well as a net decrease in operating assets and liabilities of $3.0 million. Once adjusted for the non-cash items above, the cash used in operating activities for the nine months ended September 30, 2020 was primarily driven by selling, general and administrative expenses of $21.5 million and research and development expense of $44.5 million related to the advancement of our clinical product candidates.

~~The net~~Investing Activities

Net cash used in ~~operating~~investing activities was ~~$63.9~~$136.3 million for the nine months ended September 30, ~~2019, and consisted~~2021, consisting primarily of a net ~~loss~~purchases of ~~$49.6 million adjusted for $11.5 million in net non-cash items, including unrealized gain on equity~~investment debt securities of $22.3 million, offset by the depreciation and amortization of fixed assets and right-of-use lease assets of $3.9 million, amortization of deferred financing costs and debt discount of $0.3 million, write-down of inventory of $0.9 million, change in fair value of financial instruments of $0.1 million and share-based compensation expense of $5.6 million, as well as a net decrease in operating assets and liabilities of $2.7$136.0 million. Once adjusted for the non-cash items above, the cash used in operating activities for the nine months ended September 30, 2019 was primarily driven by selling, general and administrative expenses of $18.8 million, research and development expense related to the advancement of our clinical product candidates of $42.1 million and interest paid on our debt of $2.5 million.

~~Investing Activities~~

Net cash used in investing activities was $25.2 million for the nine months ended September 30, 2020, consisting primarily of purchases of investment debt securities of $44.6 million, offset by proceeds from the sale of a portion of our investment in MeiraGTx of $19.8 million.

Financing Activities

Net cash ~~used in investing~~provided by financing activities ~~was $0.4 million~~ for the nine months ended September 30, ~~2019~~2021 was $211.1 million, consisting primarily of ~~costs related~~net proceeds from the issuance of our convertible notes of $232.4 million in Februrary 2021, offset by the payments for capped call transactions in connection with the convertible notes of $33.0 million. For more information, please refer to ~~leasehold improvements at~~Note 5 of the notes to our ~~clinical office~~unaudited consolidated financial statements included elsewhere in ~~Cambridge, MA and the purchase of laboratory equipment.~~

~~Financing Activities~~this Quarterly Report on Form 10-Q.

Net cash provided by financing activities for the nine months ended September 30, 2020 was $52.7 million, consisting primarily of net proceeds from the issuance of common stock in our ATM Offering of $48.5 million. ~~Net cash provided by financing activities for the nine months ended September 30, 2019 was $35.8 million, consisting primarily~~

‎

Table of ~~net proceeds from the issuance of common stock through the ATM Offering of $35.7 million.~~Contents

Future Funding Requirements

~~We expect~~Our operations have principally been funded through the issuance of equity and debt securities. As our ~~expenses to increase compared to prior periods in connection with~~commercialization activities and our ~~ongoing activities, particularly as we continue~~planned research and development programs continue to advance, we expect our costs will increase. Furthermore, given the uncertain economic conditions caused by the COVID-19 pandemic, we will continue to monitor the nature and ~~initiate clinical trials, seek regulatory approvals for~~extent of the impact of the COVID-19 pandemic on our ~~product candidates~~liquidity and ~~advance~~capital resources. As a result, our ~~planned commercial launch efforts for belumosudil, if approved. In anticipation of regulatory approval for any~~management will retain broad discretion over the allocation of our ~~product candidates, we expect to incur significant pre-commercialization expenses related to product sales, marketing, distribution~~existing cash, cash equivalents and ~~manufacturing.~~marketable debt securities.

The expected use of our cash, ~~and~~ cash equivalents and marketable debt securities at September 30, ~~2020~~2021 represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. ~~The amount and timing~~Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate partners or from other sources, may not be available when needed or on terms acceptable to us. Insufficient funds may require us to delay, scale back or eliminate certain of our ~~actual expenditures may vary significantly depending on numerous factors,~~research and development programs.

Our future working capital requirements, including the ~~progress~~need for additional working capital, will be largely determined by the advancement of our portfolio of product candidates and commercialization of REZUROCK. More specifically, our working capital requirements will be dependent on:

the timing, magnitude and scope of commercial spending and our development ~~the status of, and results from, clinical trials, the potential need to conduct additional clinical trials to obtain~~programs;

regulatory approval of our product ~~candidates for all intended indications, as well as any additional collaborations that we may enter into with third parties~~candidates;

the costs of obtaining patent protection for our product ~~candidates~~candidates;

the timing and ~~any unforeseen cash needs. Our funding requirements may be affected~~terms of business development activities;

the rate of technological advances relevant to our operations;

the efficiency of manufacturing processes developed on our behalf by ~~the COVID-19 pandemic to the extent timelines for clinical trials~~third parties; and product approvals may be extended and access to capital may be reduced. As a result, our management will retain broad discretion over the allocation of our existing cash, cash equivalents, and marketable debt securities. In addition, we anticipate the need to raise additional funds from the issuance of additional debt or equity securities and monetization of assets, and our management will retain broad discretion over the allocation of those funds.
‎

~~Table of Contents~~



the level of required administrative support for our daily operations.

Contractual Obligations and Commitments

There have been no material changes in our contractual obligations and commitments during the nine months ended September 30, ~~2020~~2021 from those set forth in our Annual Report on Form 10-K for the year ended December 31, ~~2019 and those disclosed in Note 12 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report~~2020, filed with the SEC on ~~Form 10-Q.~~March 4, 2021.

Off-balance Sheet Arrangements

During the periods presented we did not have, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules. We may be obligated in future periods to make contingent payments, which would become due and payable only upon the achievement of certain research and development, regulatory and approval milestones (see Note 12 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q).

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this item.

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities ~~and~~ Exchange Act of 1934, as amended, (the “Exchange Act”) is (1) recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our ~~principal executive officer~~Chief Executive Officer (“CEO”) and ~~principal financial officer,~~Chief Financial Officer (“CFO”), to allow timely decisions regarding required disclosure.

As of September 30, ~~2020,~~2021, our management, with the participation of our ~~principal executive officer~~CEO and ~~principal financial officer,~~CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the ~~Securities and~~ Exchange ~~Act of 1934, as amended)~~Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our ~~principal executive officer~~CEO and ~~principal financial officer~~CFO have concluded based upon the evaluation described above that, as of September 30, ~~2020,~~2021, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the ~~Securities and~~ Exchange Act, ~~of 1934,~~ as amended), occurred during the fiscal quarter ended September 30, ~~2020~~2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

‎

2934

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

~~None.~~From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Please refer to Note 12 of the notes to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a discussion related to our legal proceedings.

Item 1A. Risk Factors

~~Although not required~~Investing in our securities involves a high degree of risk. In addition to ~~provide~~ the other information ~~required by~~contained elsewhere in this ~~Item,~~report, you should carefully consider the ~~Company is supplementing and updating the risk~~ factors discussed in ~~its prior filings with the SEC, including those discussed under the heading “Item~~“Part I, Item 1A. Risk ~~Factors,”~~Factors” in ~~the Company’s~~our most recent Annual Report on Form 10-K for the year ended December 31, ~~2019, filed with~~2020, which could materially and adversely affect our business, financial condition or future results. These risks and uncertainties are not the ~~SEC on March 5, 2020, with~~only ones we face. You should recognize that other significant risks and uncertainties may arise in the ~~following:~~

~~Our business could be adversely affected by the effects of health epidemics and pandemics, including the recent COVID-19 pandemic, in regions where we or third parties on~~future, which we ~~rely have significant concentrations of clinical trial sites~~cannot foresee at this time. Also, the risks that we now foresee might affect us to a greater or different degree than expected. Certain risks and uncertainties, including ones that we currently deem immaterial or that are similar to those faced by other companies in our industry or business ~~operations. The COVID-19 pandemic has impacted~~in general, may also affect our operations, including at our corporate headquarters in New York, commercial operations in Pennsylvania, clinical operations in Massachusetts, research facility in New Jersey and at our clinical trial sites, as well as the business or operations of our CROs or other third parties with whom we conduct business. If ~~these impacts continue for an extended period~~any of ~~time,~~the risks actually occur, our business, financial condition or results of operations could be materially and adversely affected.

~~Our business could be adversely affected by health epidemics~~The risk factors described below update the risk factors disclosed in regions where we have clinical trial sites or other business operations and could cause significant disruption in the operations of CROs upon whom we rely. For example, in December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 has spread to multiple countries, including the United States and several European countries. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Further, the President of the United States declared the COVID-19 pandemic a national emergency. The Governors of New York, Pennsylvania, New Jersey and Massachusetts declared a state of emergency related to the spread of COVID-19, and issued orders directing all individuals, including where our headquarters is located, to “stay at home” except to perform certain essential activities. The orders took effect in March 2020. We have temporarily implemented work-from-home policies for all employees. The impacts of the state orders and our work-from-home policies have impacted productivity in certain business units, impacted management attention, depleted resources, disrupted our business and delayed our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar disruptionsPart I, Item 1A. in our ~~operations could materially~~2020 10-K to include additional information, and ~~adversely impact our business, operating results and financial condition. In addition, our clinical trials may~~should be ~~affected by~~read in conjunction with the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. For instance, due to interruptions at clinical sites, enrollment has been delayedrisk factors in our ongoing Phase 2 clinical trial of belumosudil (KD025) in systemic sclerosis and enrollment was also delayed in our ongoing Phase 1 clinical trial of KD033 in patients with metastatic or locally advanced solid tumors. Also, some patients may not be able to comply with clinical trial protocols if quarantine impedes patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations. The COVID-19 pandemic may materially affect us economically. While the economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the widespread pandemic has resulted in significant disruption of global financial markets, potentially reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. The impacts of the COVID-19 pandemic may also exacerbate other risks discussed in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, ~~2019, any of which could have a material effect on us. This situation is changing rapidly and additional impacts may arise that we are not aware of currently.~~2020.

~~Our business could be adversely affected~~If the Merger contemplated by the ~~cyber, privacy and productivity effects of remote working and disruption at management and board levels due to COVID-19.~~

We have transitioned all of our employee population to a remote work environment in an effort to mitigate the spread of COVID-19, which may exacerbate certain risks to our business, including an increased demand for information technology resources, increased risk of phishing and other cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our members or other third-parties. We may experience disruptions to our business operations resulting from quarantines, self-isolations, or other movement and restrictions on the ability of our employees to perform their jobs that may impact our ability to progress our clinical candidates in a timely manner or meet development milestones. The COVID-19 pandemic could also disrupt our operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of

~~Table of Contents~~

~~management and other employees who elect~~Merger Agreement does not to come to work due to the illness affecting others in our office or laboratory facilities, or due to quarantines. COVID-19 illness could also impact members of our Board of Directors resulting in absenteeism from meetings of the directors or committees of directors, and makingoccur, it ~~more difficult to convene the quorums of the full Board of Directors or its committees needed to conduct meetings for the management of our affairs.~~

We may not be entitled to forgiveness of our recently received Loan under the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act, and our application for the Paycheck Protection Program Loan could in the future be determined to have been impermissible or could damage our reputation.

On April 14, 2020 we received proceeds of $3.1 million from a loan under the Paycheck Protection Program (“PPP Loan”) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”), which we intend to use to retain current employees, maintain payroll and make lease and utility payments. The PPP Loan matures on April 15, 2022 and bears interest at a rate of 1% per annum. On August 20, 2020, the loan was amended so that, commencing August 15, 2021, the Company is required to pay the lender equal monthly payments of principal and interest as required to fully amortize by April 15, 2022 the principal amount outstanding on the PPP Loan as of October 15, 2020. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the eight-week period beginning on the date of loan approval. We will be required to repay any portion of the outstanding principal that is not forgiven, along with accrued interest. While we have begun preparations to apply for forgiveness, we cannot provide any assurance that we will be eligible for loan forgiveness, or that any amount of the PPP Loan will ultimately be forgiven by the U.S. Small Business Administration (“SBA”). Furthermore, on April 28, 2020, the Secretary of the U.S. Department of the Treasury stated that the SBA will perform a full review of any PPP loan over $2.0 million before forgiving the loan. In order to apply for the PPP Loan, we were required to certify, among other things, that the current economic uncertainty made the PPP Loan request necessary to support our ongoing operations. We made this certification in good faith after analyzing, among other things, the maintenance of our entire workforce, notwithstanding certain obvious “work-from-home” limitations associated with the nature of our business and managing risks to our development programs. In considering our position, the Company, an emerging growth clinical-stage biopharmaceutical research and development company with approximately 120 employees (including 27 research staff ordinarily located within the Company’s laboratories), currently conducting 6 clinical trials to develop at least 3 medicines for currently unmet and under-served medical needs, took into account our classification as a smaller reporting Company under SEC rules, our ability to currently access alternative forms of capital in the current market environment, and that management expressed substantial doubt as described in Note 1 of the financial statements in the Company’s Annual Report on Form 10-K filed with the SEC on March 5, 2020 about our ability to continue as a going concern based upon our recurring and continuing losses from operations and our need for additional funding to continue operations. The report of our independent registered public accounting firm BDO USA, LLP also included an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. Following this analysis, we believe that we satisfied all eligibility criteria for the PPP Loan, and that our receipt of the PPP Loan is consistent with the broad objectives of the PPP of the CARES Act, and following receipt of the loan, we have made no COVID-19 layoffs. The certification described above did not contain any objective criteria and is subject to interpretation. We will continue to assess our continued qualification if and when updated guidance is released by the Treasury Department. If, despite our good-faith belief that given our circumstances we satisfied all eligible requirements for the PPP Loan, we are later determined to have violated any applicable laws or regulations or it is otherwise determined that we were ineligible to receive the PPP Loan, we may be required to repay the PPP Loan in its entirety and/or be subject to additional penalties, which could also result in adverse publicity and damage to reputation. In addition, our receipt of the PPP Loan may result in adverse publicity and damage to our reputation, and a review or audit by the SBA or other government entity or claims under the False Claims Act could consume significant financial and management resources. If these events were to transpire, they could have a material adverse effect on our business, results of operations, financial condition and stock price.

On September 7, 2021, we entered into the Merger Agreement with Sanofi. Completion of the proposed Merger is subject to the satisfaction of various conditions, including the receipt of approvals from our stockholders and from government or regulatory agencies. There is no assurance that all of the various conditions will be satisfied, or that the Merger will be completed on the proposed terms, within the expected timeframe, or at all. The proposed Merger gives rise to inherent risks that include:

the amount of the cash to be paid under the Merger agreement is fixed and will not be adjusted for changes in our business, assets, liabilities, prospects, outlook, financial ~~condition.~~condition or results of operations or in the event of any change in the market price of, analyst estimates of, or projections relating to, our common stock;

legal or regulatory proceedings, including regulatory approvals from governmental entities (including any conditions, limitations or restrictions placed on these approvals) and the risk that one or more governmental entities may delay or deny approval, or other matters that affect the timing or ability to complete the transaction as contemplated;

the ability of Sanofi to obtain the necessary funds to complete the Merger;

the possibility of disruption to our business, including increased costs and diversion of management time and resources;

difficulties maintaining business and operational relationships, including relationships with clients, vendors, suppliers, distributors, resellers and other business partners;

the inability to attract and retain key personnel pending consummation of the proposed Merger;

potential stockholder litigation relating to the Merger could prevent or delay the Merger or otherwise negatively impact our business and operations;

the inability to pursue alternative business opportunities or make changes to our business pending the completion of the proposed Merger;

the requirement to pay a termination fee of $60.125 million if we terminate the Merger Agreement under certain circumstances;

developments beyond our control including, but not limited to, changes in domestic or global economic conditions that may affect the timing or success of the proposed Merger; and

the risk that if the proposed Merger is not completed, the market price of our common stock could decline, investor confidence could decline, stockholder litigation could be brought against us, relationships with clients, suppliers and other business partners may be adversely impacted, we may be unable to retain key personnel, and profitability may be adversely impacted due to costs incurred in connection with the proposed Merger.

3135

Table of Contents

~~Review~~The announcement and pendency of our ~~NDA for belumosudil under~~agreement to be acquired by Sanofi could adversely affect our business.

Uncertainty about the ~~FDA's RTOR pilot program~~effect of the proposed acquisition on our customers, employees, partners and other parties may ~~not lead~~adversely affect our business. Our employees may experience uncertainty about their roles or seniority following the acquisition. There can be no assurance that our employees, including key personnel, can be retained, or that we will be able to ~~a faster regulatory review~~attract and retain employees to the same extent that we have previously been able to. Any loss or ~~approval,~~distraction of such employees could adversely affect our business and operations. In addition, we have diverted, and will continue to divert, significant management resources toward the completion of the acquisition, which could adversely affect our business and operations. Parties with which we do ~~not increase~~business may experience uncertainty associated with the ~~likelihood that belumosudil will obtain marketing approval.~~acquisition, including with respect to current or future business relationships with us. Uncertainty may cause customers to refrain from doing business with us, which could adversely affect our business, results of operations, financial condition and stock price.

The ~~FDA~~failure to complete the acquisition by Sanofi could adversely affect our business.

Consummation of the acquisition by Sanofi is subject to several conditions beyond our control that may prevent, delay, or otherwise adversely affect its completion, including our need to obtain stockholder approval of the acquisition. If any of these conditions are not satisfied or waived, it is possible that the acquisition will not be consummated in the expected time frame (or at all) or that the definitive agreement may be terminated. If the proposed acquisition is not completed, the share price of our common stock may decrease to the extent that the current market price of our common stock reflects an assumption that a transaction will be completed. In addition, under circumstances specified in the Merger Agreement, we may be required to pay a termination fee of $60.125 million to Sanofi. Further, a failed transaction may result in negative publicity and a negative impression of us in the investment community. Any disruption to our business resulting from the announcement and pendency of the transaction and from intensifying competition from our competitors, including any adverse changes in our relationships with our customers, employees, partners and other ~~regulatory bodies periodically introduce pilot programs with~~parties, could continue or accelerate in the ~~goal~~event of a failed transaction. There can be no assurance that our business, relationships with other parties, liquidity or financial condition will not be adversely affected, as compared to the condition prior to the announcement of the acquisition, if the acquisition is not consummated.

The Merger Agreement limits our ability to pursue alternatives to the acquisition.

The Merger Agreement contains provisions that make it more ~~efficient review~~difficult for us to enter into alternative transactions. The Merger Agreement contains certain provisions that restrict our ability to, among other things, solicit, initiate or knowingly encourage or knowingly facilitate the submission of ~~applications, including~~inquiries, proposals or offers relating to or that would reasonably be expected to lead to any acquisition proposal from a third party. The Merger Agreement also provides that our board of directors will not change its recommendation that our stockholders adopt the ~~FDA OCE's RTOR pilot program, which is currently being tested by the FDA. The RTOR pilot program allows the FDA~~Merger Agreement and will not approve any agreement with respect to ~~review data before the applicant formally submits its completed application, aiming~~an acquisition proposal, subject to ~~explore a more efficient review process.~~limited exceptions.

In ~~September 2020,~~addition, upon adoption of the Merger Agreement by our stockholders, our right to terminate the Merger Agreement in response to a superior proposal will be eliminated. While we ~~submitted~~believe these provisions are reasonable, customary and not preclusive of other offers, the provisions might discourage a ~~NDA~~third party that has an interest in acquiring all or a significant part of us from considering or proposing such acquisition, even if such party were prepared to pay consideration with a higher per-share value than the currently proposed merger consideration. Furthermore, the requirement to pay a termination fee under certain circumstances may result in a third party proposing to pay a lower per-share price to acquire us than it might otherwise have proposed to pay because of the added expense of the termination fee that may become payable by us in certain circumstances.

Litigation has and may arise in connection with the acquisition by Sanofi, which could be costly, prevent consummation of the acquisition, divert management’s attention and otherwise materially harm our business.

In October 2021, ten alleged stockholders of the Company filed actions in federal courts located in the states of New York, Delaware, and Pennsylvania against the Company and the members of its Board of Directors, which claims generally allege that the Company and its Board of Directors failed to disclose allegedly material information in the definitive proxy statement on Schedule 14A, filed with the SEC on October 4, 2021 related to the ~~FDA for~~ ~~belumosudil for the treatment of patients with chronic graft-versus-host disease (cGVHD)after failure of two or more lines of systemic therapy.~~Merger. The ~~NDA remains subject to acceptance by the FDA. Acceptance by the FDA marks the commencement~~case is still pending. See Note 14 of the ~~FDA’s formal review process, and the initiation~~notes to our unaudited consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a discussion related to our legal proceedings . Regardless of the ~~regulatory deadlines under~~outcome of this or any future litigation related to the ~~Prescription Drug User Fee Act. The NDA is being reviewed under the RTOR pilot program.~~

Although the RTOR pilot program and other designations we may receive or programs we may participate in, are intended to expedite the review and approval of product candidates, they do not ensure that marketing approval will be granted in a particular timeframe, or at all. The FDA and other regulatory authorities have broad discretion whether or not to grant designations for expedited review or include product candidates within various programs, and, even if we or our partners believe a particular product candidate is eligible for these designations or programs, we cannot assure you thatacquisition by Sanofi, such authority would agree. Even if we or our partners receive such designations or our product candidates are eligible for inclusion in expedited review programs in the future, we may not experience a faster development, review, or approval process compared to conventional procedures. Furthermore, these designations and programs do not change the scientific and medical standard for approval or the quality of evidence necessary to support approval. As a result, applications for product candidates granted priority review or other expedited review designations or subject to these various programslitigation may be ~~denied based on study data, study design,~~time-consuming and expensive and may distract our management from running the day-to-day operations of our business. The litigation costs and diversion of management’s attention and resources to address the claims and counterclaims in any litigation related to the acquisition by Sanofi may materially adversely affect our business, financial condition and operating results. Further, if the acquisition is not consummated for any reason, litigation could be filed in connection with the failure to consummate the acquisition. Any litigation related to the acquisition may result in negative publicity or ~~other factors.~~an unfavorable impression of us, which could adversely affect the price of our common stock, impair our ability to recruit or retain employees, damage our relationships with our customers and suppliers, or otherwise materially harm our operations and financial performance.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.

3237

Table of Contents

EXHIBIT INDEX


Exhibit ‎Number	Description of Exhibit
~~3.1~~2.1	~~Restated Certificate~~Agreement and Plan of ~~Incorporation~~Merger, dates as of September 7, 2021, by and among Kadmon Holdings, Inc., Sanofi and Latour Merger Sub, Inc. (incorporated herein by reference to Exhibit ~~3.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37841), filed with the SEC on August 5, 2019).~~
~~3.2~~	~~Certificate of Designations of Kadmon Holdings, Inc. creating the 5% Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.3~~2.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37841), filed with the SEC on ~~August 1, 2016)~~September 8, 2021).
~~3.3~~10.2	~~Bylaws of~~Second Amendment to Employment Agreement between Kadmon ~~Holdings, Inc.~~Corporation, LLC and Harlan W. Waksal, M.D., dated September 7, 2021 (incorporated herein by reference to Exhibit ~~3.2~~10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37841), filed with the SEC on ~~August 1, 2016)~~September 8, 2021).
10.3	Second Amendment to Employment Agreement between Kadmon Corporation, LLC and Steven Meehan, dated September 7, 2021 (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37841), filed with the SEC on September 8, 2021).
10.4	Second Amendment to Employment Agreement between Kadmon Corporation, LLC and Gregory S. Moss, dated September 7, 2021 (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No. 001-37841), filed with the SEC on September 8, 2021).
31.1*	Certification of ~~Principal~~Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of ~~Principal~~Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	~~Certifications~~Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	~~Certifications~~Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*	Inline XBRL Taxonomy Extension Schema
101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*	Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*	Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101)
*	Filed herewith.
**	Furnished herewith. ~~In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the~~The certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange ~~Act.~~Act, irrespective of any general incorporation language contained in such filing.

3338

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kadmon Holdings, Inc.



Date: November ~~5, 2020~~4, 2021	By:	/s/ Harlan W. Waksal Harlan W. Waksal ‎President and Chief Executive Officer (Principal Executive Officer)

Date: November ~~5, 2020~~4, 2021	By:	/s/ Steven Meehan Steven Meehan ‎Executive Vice President, Chief Financial Officer (Principal Financial Officer)
Date: November ~~5, 2020~~4, 2021	By:	/s/ Kyle Carver
		Kyle Carver ‎~~Principal~~Senior Vice President, Chief Accounting Officer, Controller
		(Principal Accounting Officer)

3439